No retraction, correction or concern found when last checked on Oct 22, 2026.

P2X7 in Cancer: From Molecular Mechanisms to Therapeutics

Romain Lara, Elena Adinolfi, Catherine A. Harwood and 4 more

Frontiers in Pharmacology · 2020 · Review · CC BY

doi:10.3389/fphar.2020.00793

Abstract

P2X7 is a transmembrane receptor expressed in multiple cell types including neurons, dendritic cells, macrophages, monocytes, B and T cells where it can drive a wide range of physiological responses from pain transduction to immune response. Upon activation by its main ligand, extracellular ATP, P2X7 can form a non-selective channel for cations to enter the cell. Prolonged activation of P2X7, via high levels of extracellular ATP over an extended time period can lead to the formation of a macropore, depolarisation of the plasma membrane and ultimately to cell death. Thus, dependent on its activation state, P2X7 can either drive cell survival and proliferation, or induce cell death. In cancer, P2X7 has recently been shown to have a broad range of functions, including playing key roles in the development and spread of tumour cells. It is therefore unsurprising that P2X7 has been reported to be up-regulated in several malignancies. Critically, ATP is present at high extracellular concentrations in the tumour microenvironment (TME) compared with levels observed in normal tissues. These high levels of ATP should present a survival challenge for cancer cells, potentially leading to constitutive receptor activation, prolonged pore formation and ultimately to cell death. Therefore, to deliver the proven advantages for P2X7 in driving tumour survival and metastatic potential, the P2X7 macropore must be tightly controlled whilst retaining other functions. Studies have shown that commonly expressed P2X7 splice variants, distinct SNPs and post-translational receptor modifications can impair the capacity of P2X7 to open the macropore. These receptor modifications and potentially others may ultimately protect cancer cells from the negative consequences associated with constitutive activation of P2X7. Significantly, the effects of both P2X7 agonists and antagonists in preclinical tumour models of cancer demonstrate the potential for agents modifying P2X7 function, to provide innovative cancer therapies. This review summarises recent advances in understanding of the structure and functions of P2X7 and how these impact P2X7 roles in cancer progression. We also review potential therapeutic approaches directed against the receptor.

Full text

From PubMed Central, U.S. National Library of Medicine, as current on Oct 22, 2026. Paragraph numbers are ours, so an answer can point at one.

Introduction

1Extracellular ATP is a danger associated molecular pattern (DAMP), which can act through the P2 receptor family including ionotropic P2X ion channel receptors and the G protein-coupled P2Y receptor family. The P2X receptor family is formed by seven members able to assemble into homo- and hetero-trimers at the cell membrane. P2X family members are distinguished by their relative affinities to ATP, within the nanomolar range for P2X1 and P2X3, the low micromolar range for P2X2, P2X4, and P2X5 and the hundreds of micromolar range for P2X7 and also their rate of channel desensitization, milliseconds for P2X1 and P2X3, seconds for P2X2, P2X4, and P2X5 and no observable desensitization for P2X7,.

2P2X7 is characterized by its biphasic response to ATP stimulation. Upon activation with ATP for a relatively short period (2s or less), P2X7 opens a nonselective cation channel facilitating Na+ and Ca2+ influx and K+ efflux while prolonged ATP stimulation (4s or above) leads to the formation of a macropore permeable to molecules of <900 Da. However, recent reports have shown that ATP activated P2X7 receptors can open a NMDG+-permeable macropore within milliseconds and without progressive dilatation. Formation of this large molecular weight-permeable pore has been associated with the release of ATP in the microenvironment. Extracellular ATP helps to sustain macropore opening and is likely to drive several physiological and pathological mechanisms including chronic pain, proliferation and activation of microglia and the death of enteric neurons during colitis. In healthy tissues, P2X7 is expressed mainly in the central nervous system (CNS), peripheral nervous system (PNS), and in immune cells, which supports its emergence as a target for chronic pain and chronic inflammatory diseases. P2X7 is also overexpressed in a number of cancer types, potentially driving tumor development and survival.

3As a consequence of its ion channel activity, P2X7 is involved in driving several functions known to be important during tumor initiation and progression. Yet, analysis of sequencing repositories from large tumor panels, including deep sequencing initiatives, does not highlight the preferential selection of mutation or copy number variation in the P2RX7 gene by tumor cells. This suggests that other receptor control mechanisms might modulate the critical role P2X7 plays during cancer progression. Extracellular ATP is present at low levels in healthy tissues but increases dramatically in response to tissue damage, inflammation, hypoxia, ischaemia and in the tumor microenvironment (TME). This increase in extracellular ATP has been attributed to cell death, cell stress, vesicular release, activation of pannexin and connexin, and to ATP-binding cassette (ABC) transporters. In the TME, extracellular ATP is hydrolyzed into AMP by the ectonucleotidase CD39, AMP is then hydrolyzed into adenosine by the CD73 ectonucleotidase. While extracellular ATP acts as a DAMP to trigger proinflammatory immune responses, adenosine was found to be a potent immunosuppressor. In this context, P2X7 collaboration with purinergic related proteins such as CD39 and Pannexin 1, was found to play an important role in the regulation of the antitumor immune response.

4The high extracellular ATP concentration found in the TME is sufficient to open the P2X7 macropore that could in turn lead to membrane depolarization and ultimately to cell death. To support tumor progression, cancer cells need to inhibit P2X7 macropore activity while retaining other receptor signaling functions. Several studies have described molecular mechanisms that lead to loss or attenuation of macropore function (See Table 1 ). These include the report of a misfolded form of P2X7 termed nonfunctional P2X7 (nfP2X7) that is characterized by the exposure of an extracellular epitope named E200. In this review we seek to describe how the interplay between P2X7 functions drive tumor progression and immune escape. We first present the topological features, functions and processes activated downstream of the P2X7 receptor before discussing how the interplay between these features may explain the paradoxical role of P2X7 in the tumor and the immune compartment. We then discuss the expression and role of P2X7 across multiple cancer types before reviewing the therapeutic approaches taken to target P2X7 to date.

Topology of the P2X7 Receptor

5The human P2RX7 gene is located on chromosome 12 and encodes 13 exons that translate into a 595 amino acid protein. The location of P2RX7 (12q24.31) is adjacent to the P2RX4 gene, which is only 20Mbp downstream in the same reading direction. Both genes are believed to be derived from successive gene duplications. Indeed, a recent report suggests that P2X7 was probably formed in lower vertebrates through the fusion of a P2X4-like gene with a Zn-coordinating cysteine-based domain (ZCD) coding exon. While heteromerisation of P2X7 and P2X4 in vivo is still controversial, both genes are found to be widely coexpressed and colocalize to act in concert in the regulation of the same physio-pathological functions. Thirteen P2X7 splice variants have been identified to date. While the resolution of the structure of human P2X7 has not yet been achieved, due to its propensity to aggregate, the partial structure of human P2X3, zebra fish P2X4, chicken P2X7, panda P2X7, and more recently the full-length rat P2X7 have been resolved. These have begun to reveal the molecular mechanism of ATP channel gating and the topology of the P2X7 trimer at the cell membrane. The P2X7 receptor is divided into five main structural domains ( Figure 1 ).

N-Terminal Cytoplasmic Tail

6A short N-terminal cytoplasmic tail of 25 amino acids (aa), which is anchored in the membrane via the palmitoylation of a cysteine residue at position 4 to form a cytoplasmic cap involved in the sensitisation of the channel to its agonist through key residues such as T15 and Q17.

First Transmembrane Domain (TM1) and Extracellular Domain

7The N-terminal cytoplasmic tail is followed by a first transmembrane domain named TM1 (aa 26 to 46) and a large extracellular domain of 282 aa (aa 47 to 329), which contains an inter-subunit ATP binding pocket. The extracellular domain also includes 5 disulfide bonds between cysteine residues 119–168, 129–152, 135–162, 216–226, and 260–269, which play a critical role in maintaining the conformation of the extracellular domain. These disulfide bridges are homologous across the other members of the P2X receptors which suggest that they form highly conserved protein folds. Several post-translational modifications have been identified in the P2X7 extracellular domain which can regulate receptor functions; these include ADP-ribosylation of R125 on murine P2X7 that is involved in the gating of the murine P2X7 receptor and N-linked glycosylation of 5 asparagine residues (D187, D202, D213, D241, and D284) with D187 N-linked glycosylation playing a key role in the regulation of P2X7 signaling through the MAP kinase pathway.

Second Transmembrane Domain (TM2)

8The extracellular region is followed by a second transmembrane domain named TM2 (aa 330 to 349), which contains several key pore-lining residues. These include S342, which sits at the narrowest part of the channel to regulate its gating. Phosphorylation of the adjacent Y343 also regulates channel gating which further emphasizes the importance of those two residues during channel gating.

C-terminal Cytoplasmic Tail

9The second transmembrane domain is flanked by a long C-terminal cytoplasmic tail of 245 aa (aa 350 to 595), which acts as a ballast and is involved in the modulation of macropore opening. The beginning of the C-terminal tail contains a cysteine rich region that is palmitoylated on at least five residues (C362, C363, C374, C377, and S360) and plays an important role in trafficking of the receptor to the cell membrane and in preventing receptor desensitization. These multiple palmitoylated residues act as a hinge allowing each C-terminal tail to create two zinc binding sites and a guanosine diphosphate or triphosphate (GDP/GTP) binding site. From a functional perspective, the C-terminal tail has been shown to be required for the opening of the macropore. Recent reports have also shown that pore opening requires movement of the TM2 helix which is directly linked to the globular ballast folded underneath. This suggests that a significant movement of the ballast is needed to allow for the macropore to form (See Figures 1 and 2 ). Given the presence of GDP/GTP binding sites in the P2X7 C-terminal tail, it is tempting to hypothesize that such a structural rearrangement may involve an exchange between GDP and GTP. This type of mechanism has already been extensively characterized for GTPase enzymes, which promote the hydrolysis of GTP to GDP to trigger protein interaction and signaling cascades. This switch could either be mediated by P2X7 itself or through accessory proteins such as GTPase-activating proteins (GAPs) and guanine nucleotide exchange factors (GEFs). However, further work is needed to confirm this hypothesis.

P2X7 Possesses Ion Channel Functionality

10P2X7 is distinguished from other P2X family members by its relative insensitivity to its natural agonist ATP (EC50 above 80 −100 µM). ATP binding to the inter-subunit pocket leads to a rotation of each subunit around its turret and a widening of the lower body of the P2X7 trimer. This conformational rearrangement is associated with the opening of a lateral fenestration in the lower body of the trimer that in turn allows influx of Ca2+ and Na+ ions into and the efflux of K+ ions from the cell ( Figures 2A, B ). Several well characterized small molecule inhibitors have been reported to inhibit this mechanism through binding to an allosteric pocket located in between the turret of each subunit, thereby preventing the closure of the turret necessary for the opening of the channel ( Figures 2A, B ). Observations made using rat P2X7 suggest that the C-terminal cytoplasmic tail does not significantly regulate receptor current facilitation, desensitization, affinity for ATP or its receptor ion selectivity.

11Structural analysis of P2X family members together with experimental characterization and mathematical modeling have provided insights into the transition states of the P2X7 receptor following ATP binding. While occupation of all three ATP binding sites on the trimer leads to a symmetric conformational rearrangement and to channel gating, the binding of a single ATP molecule leads to an asymmetric rearrangement of the trimer leaving the fenestration closed and decreasing the affinity of the second and third ATP binding sites. Upon binding of a second ATP molecule, a low conductance is observed with a further decrease in the affinity of the third ATP binding site. These observations explain why P2X7 is relatively insensitive to ATP compared to other P2X family members. The functional implication is that P2X7 ion channel activation is only achieved when the level of ATP is significantly elevated in the extracellular compartment. Such conditions can be found in the TME, during inflammatory responses and in chronic inflammatory diseases. In these settings, P2X7 mediated calcium signaling was shown to trigger intracellular signaling and changes in gene expression that are critical for cancer cell survival and proliferation. Indeed, overexpression of full length P2X7 was shown to promote tumor growth, while P2X7 blockade was shown to inhibit neoplastic growth in several experimental models.

P2X7 Activation Can Open a Transmembrane Macropore

12Evidence for ATP-induced dye uptake was first identified in the 1970s and 80s but it was only a decade later that P2X7, previously known as P2Z, was shown to play a key role in the formation of a transmembrane dye-permeable macropore. The formation of a transmembrane pore is not believed to be limited exclusively to P2X7. Other ion channels including P2X2, P2X4, TRPV1 and ASICs have also been shown to increase conductance and allow molecules of <900 Da into the cell. However, while P2X2, P2X4, TRPV1, and ASICs undergo a “channel to pore dilatation” upon prolonged activation, P2X7 pore opening is almost instantaneous (within milliseconds).

13While demonstration of the P2X7 macropore has been described extensively in vitro, opening of the macropore in vivo remains to be demonstrated. Opening of the macropore allows the flow of ions across the membrane leading to rapid membrane depolarization and ultimately to cell death. In vitro assessment of macropore opening is typically performed by measuring the increase in fluorescence associated with the influx of ethidium+ (314 Da), YO-PRO-12+ (375 Da), Lucifer yellow (444 Da), DAPI (277 Da) or the current associated with N-methyl-D-glucamine+ (NMDG+, 195 Da) influx. Given the significant risk that an open macropore may have on cell viability, the low sensitivity of P2X7 for ATP provides a first mechanism of protection for cells. Furthermore, P2X7 macropore opening has been shown to be reversible upon the removal of ATP within 10 to 15 min from initiation of stimulation in a mouse macrophage cell line, however reversibility may be cell type specific. This reversible closure of the macropore can potentially provide a second mechanism to protect cells from P2X7-mediated cell death. Although the advantages of gated opening of the P2X7 pore are not well understood, such transient mechanisms could allow small molecules, such as peptides and micro-RNA, to enter or leave the cell as observed for connexins and pannexins at cell to cell junctions. The demonstration that P2X7 is permeable to the large natural cation spermidine, a polyamine molecule involved in cell survival, supports this hypothesis. Since opening of a high conductance transmembrane conduit has inevitable dire consequences on cell survival, it is likely that under more physiological conditions, localized opening of the P2X7 macropore occurs that will perturb cytoplasmic ion homeostasis at discrete sites only.

14The mechanism(s) leading to macropore opening have been the subject of much controversy. Several hypotheses have been proposed to support P2X7 dilatation in response to sustained agonist stimulation and the involvement of associated proteins such as pannexin-1 (Reviewed in). However, recent analysis of human and rat P2X7 electrophysiological activity in response to agonist shows that the macropore function is intrinsic to P2X7 and does not involve progressive pore dilatation. Extracellular ATP is present at concentrations in the low nanomolar range in healthy tissue but can increase dramatically upon tissue damage, inflammation or during tumor development to the tens to hundreds of micromolar range and reach the high activation threshold of 0.3 to 0.5mM for P2X7. We demonstrated that antibodies raised against the E200 epitope of P2X7 bind specifically to cancer cell lines that are devoid of macropore function but that retain P2X7 ion channel function. In these cell lines, overexpressed wild type P2X7 rescues macropore function but is not detected by antibodies that target E200 supporting the specific exposure of E200 epitope by nfP2X7. E200 specific antibodies were used to show that nfP2X7 is present intracellularly and can be released to the plasma membrane upon stimulation with KM11060, a small molecule corrector that increases the secretion rate of misfolded proteins to the membrane as shown previously for the Cystic Fibrosis Transmembrane Receptor (CFTR) mutants. nfP2X7 was also shown to be necessary for cell survival. Hence, these data suggest that to sustain growth without compromising survival, cancer cells expressing high levels of P2X7 have developed a mechanism to inhibit macropore function while retaining ion channel functionality.

15Although mutations of P2X7, such as E496A, have been shown to abrogate the macropore, we and others have demonstrated that P2X7 is expressed at the cell membrane in the absence of mutations such as E496A. This suggests that additional mechanisms are involved in protecting cancer cells. Indeed, several other mechanisms have been shown to modulate P2X7 macropore activity. These include splice variants, N-glycosylation, ADP-ribosylation, proteolytic cleavage, and interactions with binding partners or other P2X family members. They also include interactions with cholesterol in the membrane, that may attenuate or abrogate P2X7 macropore formation (summarized in Table 1 ). One or more of these mechanisms has the potential to protect cells that possess P2X7 receptors in a high ATP microenvironment over a sustained time period.

P2X7 as a Scavenger Driving Phagocytosis

16Further to its ability to open an ion channel and macropore, P2X7 has also been shown to act as a scavenger receptor promoting phagocytosis of nonopsonised targets such as apoptotic cells, latex beads and live or dead bacteria (Staphylococcus aureus and Escherichia coli) under serum free conditions. Binding of P2X7 to the nonmuscle myosin heavy chain (NMMHC-IIA) was shown to be required for the engulfment of particles. This function is inversely correlated with P2X7 macropore opening, which requires NMMHC-IIA dissociation from P2X7 upon ATP stimulation. P2X7 mediated phagocytosis was first demonstrated in monocytes and macrophages before being extended to microglia cells in the CNS where it plays a critical role in the clearance of nonopsonised particles and debris involved in neuro-inflammation. The ability of the P2X7-NMMHC-IIA complex to act as a scavenger suggests another P2X7-mediated role for macrophages infiltrated in the TME where P2X7 would recognize and promote the phagocytosis of apoptotic cells and potentially support the presentation of associated antigen to immune effector cells. Indeed, during inflammation and in the TME, the extracellular ATP concentration is significantly higher than in healthy tissues. Under these conditions, P2X7 (as well as P2X4) stimulation potentiates phagocytosis by inflammatory macrophages.

Downstream Effect of P2X7 Activation

17Several signaling pathways are activated downstream of P2X7 including hypoxia and proinflammatory pathways via hypoxia-inducible factor 1a (HIF-1α), nitric oxide synthase (NOS2), cyclooxygenase 2 (COX2) and acute phase protein pentraxin-3 (PTX3). Downstream effects of P2X7 activation also include survival and proliferation pathways such as the NF-κB, NFATc1, Phosphoinositide 3-kinases (PI3Ks), mitogen-activated kinases (MAPK), phospholipase A2, C and D acid sphingomyelinase and myc oncogene.

18The regulation of downstream signaling pathways by P2X7 is defined at three levels. First, the concentration and duration of agonist exposure. While acute exposure to relatively high amounts of ATP has been shown to activate PI3K/AKT and AMPK-PRAS-40-mTOR signaling pathways to trigger tumor cell death, lower and chronic activation has been shown to activate the NOD-like receptor containing a pyrin (NLRP3) inflammasome pathway. Second, regulation may involve the interaction of P2X7 with other membrane proteins, such as other P2X family members or Pannexin 1. Third, interaction with scaffolding proteins associated with the cytoskeleton such as NMMHC-IIA. Indeed, the P2X7 receptor signaling complex has been shown to regulate the macropore and interact with the actin cytoskeleton machinery. These three levels of regulation are involved in several mechanisms that are key to cancer progression.

Cell Death

19The early discovery of the P2X7 macropore drove interest in P2X7 as a receptor capable of mediating cell death through disruption of intracellular homeostasis and cytolysis leading to necrosis. However, many reports have highlighted cell death mechanisms associated with P2X7 activation that are typical of an apoptotic pathway. These include membrane depolarization, redistribution of phosphatidylserine (PS) to the outer membrane, caspase 3, 8 and 9 activation and membrane blebbing. Interestingly, the recent resolution of the rat P2X7 structure has highlighted the presence of a putative phospholipid in a perpendicular position to the transmembrane helices in the middle of the plasma membrane that led McCarthy and colleagues to suggest that P2X7 might possess an intrinsic flippase-like function driving PS redistribution to the outer membrane.

Proliferation

20The notion that the P2X7 receptor, together with mediating cytotoxic activity, also exerts a proliferative drive dates back to 1999, when in a pivotal paper from Baricordi and colleagues, it was demonstrated that transfection with the receptor conferred a proliferative advantage to leukaemic cell lines growing in the absence of serum. In the following years, the trophic activity of P2X7 was associated with an increase in mitochondrial function leading to an augmented production of intracellular ATP and, in general, to increased levels of calcium inside cellular stores.

21P2X7 calcium channel activity plays a central role in driving proliferation and is shared by the human splice variant P2X7B that retains ion channel activity while losing the ability to form a macropore. When transfected in the osteosarcoma cell line Te85, P2X7B causes an increase in proliferation that is even greater than that attributable to transfection of P2X7A. Several calcium-related intracellular pathways involved in cell proliferation were shown to be activated by the P2X7 receptor. These include the JNK/MAPK, PI3K/AKT/myc and HIF1α-VEGF pathways. Among these, the nuclear factor of activated T cells (NFAT) pathway is one of the best characterized. NFAT is a calcium-calcineurin activated nuclear factor involved in the proliferation of several cell types including T lymphocytes where P2X7-dependent activation of NFAT was shown to facilitate clonal expansion and IL-2 secretion thus positively influencing lymphocytic growth. NFATc1 mediated pathway was also responsible for increased proliferation of HEK-293 and Te85 cells transfected with both P2X7A and B isoforms and was found to be upregulated in xenografts overexpressing the receptor.

22Association between P2X7, proliferation and survival has been demonstrated in several primary cell types including osteoblasts, microglia, and CD8+ memory T cells where it supports physiological functions such as inflammatory responses and osteogenesis. However, increased P2X7 activity was also linked with increased proliferation and survival in many cancer cell types including pancreatic cancer, leukemia and glioma. Indeed, reports showing enhanced P2X7 expression in tumor tissues compared with normal tissue across many cancer types suggest a role for P2X7 during tumorigenesis (See section: The function and expression of P2X7 across cancer types below). Following the demonstration of the growth-promoting activity of P2X7 in vitro, it was also shown in several studies that P2X7 can influence in vivo tumor growth and that consequently, down-modulation of the receptor by silencing or pharmacological intervention can reduce tumor burden in preclinical models. Adinolfi and colleagues first demonstrated the growth-promoting activity of P2X7 in four different tumor models in mice including HEK-293 cells and ACN neuroblastoma derived xenografts and syngeneic colon carcinoma and melanoma models. Several studies have confirmed these data and extended them, demonstrating that P2X7 blockade leads to a general reduction of tumor burden in neuroblastoma, mesothelioma, melanoma, glioma, osteosarcoma and myeloid leukemia.

Autophagy

23Autophagy is an important mechanism that maintains cell homeostasis by eliminating damaged cellular components and recycling them via metabolic pathways. By doing so, autophagy safeguards energy production under cellular stress such as starvation. Depending on the time of activation, autophagy can either help to prevent cancer or exert a tumor-promoting action. While data supporting P2X7 involvement in autophagy and cancer progression are limited, the receptor is known to act on several pathways related to autophagy including the pathway leading to autophagosome formation. Indeed, P2X7 was shown to activate autophagosome-lysosome fusion by upregulating Beclin1 and LC3-II. In dystrophic myoblasts, P2X7-dependent activation of autophagy correlated with the ability to form the macropore but not calcium influx-induced signaling. The first demonstrations of P2X7-mediated trophic activity were obtained by growing cells under serum starvation where autophagy is typically induced. Cancer cells cultured under these conditions were found to upregulate P2X7 expression suggesting that autophagy can drive P2X7 overexpression and consequent trophic activity.

24Chemotherapy-induced autophagy can be central in the modulation of the anticancer immune response. In particular, autophagy is a key driver in immunogenic cell death (ICD), a form of cancer cell death, which can elicit a potent immune response mediated by dendritic cells (DCs) and CD8+ T lymphocytes that can eradicate residual tumor cells and prevents metastasis formation following a first therapeutic intervention. Several classes of chemotherapeutics such as anthracyclines and oxaliplatin, are known to cause the induction of ICD. Before ICD takes place, premortem autophagy is required for the release of ATP in the TME where ATP attracts antigen-presenting cells via P2Y2 receptors and down-regulates Treg infiltration, to favor an antitumor immune response. Although a clear correlation between P2X7 activation and ICD in the TME is not available, it was recently demonstrated that P2X7 expression modulates ATP levels in the TME affecting CD73 and CD39 ectonucleotidase and reducing Treg levels and fitness. P2X7 systemic blockade activated an ICD–like mechanism in cancer cells leading to tumor growth reduction and activation of antitumor responses while reducing the tumor-promoting inflammatory cytokine IL-1β.

Role of P2X7 in the Immune Response

25Analysis of data from P2X7 small molecule inhibitors and genetic knock out of P2RX7 has demonstrated the key role played by P2X7 in inflammation and immunity and, as a consequence, in chronic inflammatory diseases such as Duchenne muscular dystrophy, rheumatoid arthritis and inflammatory bowel disease. In the TME, the permanent release of DAMPs including ATP, high mobility group box 1 (HMGB1) and calreticulin (CRT) drives chronic inflammatory settings that are supplemented by immunosuppressive signals leading to a dampening of immune effector cell responses. By responding to ATP proinflammatory signals, P2X7 counterbalances the potent immunosuppressive signaling driven by the ATP degradation product, adenosine. In the following section, we describe the role of P2X7 in inflammation and immunity and use this as a foundation to define the role of P2X7 in the TME.

26ATP, released through pannexin-1 hemichannels leads to activation of P2X7 as well as other P2 receptors including P2X1, P2X4, P2X5 and P2Y6 and is associated with the activation of T-cells. However, the role of P2X7 in response to extracellular ATP appears to be central to the proinflammatory response including the stimulation of CD4+ and CD8+ effector T cells, stimulation of natural killer T cells, inhibition of differentiation in type 1 regulatory cells, promotion of Treg cell death and the differentiation of inflammatory Th17 lymphocytes. P2X7 was also found to collaborate with P2Y2 to promote the chemotaxis of myeloid cells including macrophages, neutrophils and the recruitment and activation of DCs. P2X7 activation also promotes the immunosuppressive role of myeloid-derived suppressor cells (MDSCs) infiltrated in the TME by stimulating the release of reactive oxygen species (ROS), arginase 1 (ARG1) and transforming growth factor-β1 (TGF-β1).

27At the molecular level, P2X7 plays a central role in the assembly and maturation of the NLRP3 inflammasome leading to the activation of caspase 1 followed by the cleavage of pro-interleukin 1 beta (pro-IL-1β) into mature IL-1β before IL-1β is released by macrophages and other immune cells. Direct interaction of P2X7 with the components of the inflammasome including the apoptosis-associated speck-like protein containing a caspase recruitment domain (ASC) and the NOD-like receptor family (NLR) has been shown in neurons, astrocytes and microglial cells. However, following opening of the P2X7 ion channel in response to the binding of ATP, it is the depletion of cytoplasmic K+ that is the main driver leading to inflammasome activation. While other channels also mediate K+ efflux in response to ATP, P2X7 activated K+ efflux together with Ca2+ influx remain central to inflammasome activation and the secretion of cytokines and chemokines. Among these, IL-1β is a key proinflammatory cytokine secreted in response to P2X7 activation of the inflammasome. Other cytokines and chemokines are also secreted by a variety of cell types. These include IL-6, IL-8, IL-18, tumor necrosis factor alpha (TNFα), CC-chemokine ligand 2 (CCL2 also named MCP-1), CCL3, CCL7, CXCL2, and prostaglandin E2 (PGE2). P2X7 also triggers activation and shedding of matrix metalloproteases (MMPs) from peripheral-blood mononuclear cells (PBMCs). It also has been suggested that P2X7 plays a role in the resolution of inflammation through secretion of the anti-inflammatory cytokines IL-10 and TGFβ and proteins such as annexin A1. However, other reports have demonstrated P2X7 mediated inhibition of soluble HLA-G and IL-10 secretion by monocytes and the negative modulation of HLA-G in women affected with herpes virus 6 A.

28P2X7 may cooperate in mediating the response to pathogen-associated molecular patterns (PAMPs) such as lipopolysaccharides (LPS) through a potential LPS binding motif in the P2X7 C-terminal tail. LPS activation of TLR receptor also stimulates the production of pro-IL-1β, which is then processed by caspase-1 following P2X7 and NLRP3 inflammasome activation. Similarly, TLR2 and 4 were found to cooperate with P2X4 and P2X7 when activated by biglycan, a ubiquitous leucine-rich repeat proteoglycan found in the extracellular matrix. P2X7 was shown to interact with the myeloid differentiation primary response 88 (MyD88) to activate the NF-kB signaling pathway. MyD88 mediates NF-kB signaling downstream of the TLR receptors and might mediate the cooperation between P2X7 and TLR signaling pathways. P2X7 together with CD14 as a coreceptor was found to support LPS binding and the internalization of P2X7. Overall, these studies support a model whereby activation of TLR2 and 4 cooperate with P2X7 to drive chronic inflammatory settings. While ATP, PAMPs and biglycan were found to be key ligands of P2X7 and TLR receptors, in the TME, DAMPs such as ATP and HMGB1, a ligand for TLR4, are also present in significant concentrations and capable of driving the chronic inflammatory settings described above.

Role of the P2X7 in Immunometabolism

29Metabolic reprogramming and the maintenance of mitochondrial fitness are increasingly recognized as key factors in T lymphocyte differentiation and effector functions. Generation of long-lived T memory cells depends on efficient oxidative phosphorylation and fatty acid oxidation, while effector T cells are mainly dependent on glycolysis. Therefore, mitochondria have a central role in directing T cell functions. The receptors and pathways mediating the regulation of mitochondrial metabolism modulation in T cells are still poorly characterized, however it is increasingly clear that the P2X7 receptor plays an important role. P2X7 has long been known as a prototypic cytotoxic receptor, but its tonic activity also supports healthy mitochondrial metabolism, enhances ATP production via the respiratory chain and promotes cell growth. The specific role of P2X7 in supporting metabolic fitness of long-lived T memory cells has now been demonstrated. Stimulation of the P2X7 receptor via extracellular ATP is crucial to promote memory CD8+ T cell generation and long-term survival that is mediated mainly by a trophic effect on mitochondrial metabolism and the related increase in ATP synthesis. These data support a previous report from Di Virgilio and coworkers showing that P2X7 receptor expression has a broad effect on immunometabolism through modulation of glycolysis. Indeed, aerobic glycolysis is also impaired in P2X7-deficient CD8+ T lymphocytes. Thus, the P2X7 receptor may function as a “metabolic sensor” that links the DAMP extracellular ATP, to the intracellular energy-producing machinery (i.e., oxidative phosphorylation and glycolysis).

30The “metabolic sensor” function of the P2X7 receptor is of particular relevance at inflammatory and tumor sites since the extracellular ATP concentration in the inflammatory or tumor microenvironments (IME and TME, respectively) is several-fold higher than in the healthy interstitium. The impact of such a high extracellular ATP concentration on the viability of tumor infiltrated lymphocytes due to opening of the macropore is not known. While it is possible that loss of viability may take place, the long-term presence of infiltrated lymphocytes suggests that modulation of abrogation of macropore function through one or more of the mechanisms described in Table 1 is likely to take place in these cells. Although details of the mechanism whereby P2X7 ‘transduces’ the information carried by high extracellular ATP is not fully known, key immune functions are significantly affected by P2X7 activation. Most importantly, P2X7 is a major stimulus for Il-1β and IL-18 release, and therefore for the initiation of inflammation, potentiation of antigen presentation by DCs and an efficient immune response, including antitumor immune responses. Converging reports by multiple laboratories have confirmed the initial observation by Di Virgilio and coworkers of a potent P2X7-mediated growth-promoting and stimulatory effect on human T lymphocytes. P2X7 is upregulated in Treg and T follicular helper cells (Tfh) that are severely inhibited by its activation. This is hypothesized to have important implications for host-microbiota interaction in gut-associated secondary lymphoid organs where ATP released by bacteria down-modulates the activity of resident Tfh cells, thus reducing secretion of high affinity IgA and their binding to commensal bacteria. Grassi and coworkers have shown that P2X7 deletion affects microbiota composition and, in consequence, host metabolic homeostasis. This might be significant in view of the known role of microbiota in the pathogenesis of several types of cancer and the influence of microbiota on the response to immune checkpoint inhibitors.

P2X7 and Purinergic Signaling in Antitumor Immunity

31The function of the P2X7 receptor in the TME is better understood in the context of the overall mechanisms that control the extracellular ATP concentration. Of importance is the role of CD39 and CD73 ectonucleotidases, that hydrolyze ATP to adenosine. Adenosine has long been considered one of the main drivers of immunosuppression. Yet, recent data demonstrates that the P2X7, CD39, and CD73 axis also plays a significant role in the modulation of the TME immune component. P2X7 activation can be promoted by targeting CD39, with beneficial effects on antitumor responses that cannot be explained merely by the inhibition of adenosine generation. The use of P2X7 targeted small molecule inhibitors and P2RX7 genetic knock out in a murine melanoma model leads to modulation of CD39 and CD73 expression levels on several immune cell populations including Tregs, CD4+ effector lymphocytes, macrophage and DCs. P2X7 null mice show a decrease in tumor-infiltrated CD8+ T cells and an increase in Tregs overexpressing the fitness markers PD-1, OX40, and CD73. This outcome correlated with a decrease of extracellular ATP levels. In contrast, systemic inhibition of P2X7 with the antagonist A740003 did not affect the number of tumor-infiltrated CD8+ and Treg lymphocytes but increased the number of CD4+ effector T cells. A reduced expression of CD39 and CD73 was also observed on CD4+ T cells and in DCs highlighting the importance of the crosstalk between P2X7, CD39, and CD73 in these cell types. The collaboration between P2X7 and CD39 was further demonstrated in two recent studies investigating the antitumoral activity of a CD39 blocking antibody. Blocking of CD39 led to reduced tumor burden and metastatic spread in several murine models. Anti-CD39 antitumoral activity required the activation of P2X7 on immune cells as P2X7-mediated activation of the NLRP3 inflammasome led to IL-18 release by myeloid cells and induction of pyroptosis. These data demonstrate that P2X7 collaboration with CD39 plays a central role in the regulation of anti-tumor immunity.

Membrane Blebbing

32Membrane blebbing consists of plasma membrane sections protruding and retracting to create protrusions at the cell surface. Although the mechanism leading to membrane blebbing is not fully understood, P2X7 is one of the proteins that have been shown to initiate this mechanism upon sustained ATP stimulation for several minutes. ATP mediated opening of the P2X7 macropore leads to a large Ca2+ influx that can induce membrane blebbing. Multiple proteins are involved in this mechanism. These include the serine/threonine kinase ROCK I, heat shock protein HSP90 that negatively regulates receptor-mediated blebbing and the epithelial membrane protein 2 (EMP-2). EMP-2 was shown to interact with the P2X7 C-terminal tail suggesting that P2X7 mediated blebbing requires opening of the macropore. While membrane blebbing is commonly associated with cellular stress and the initiation of the apoptotic pathway, P2X7 may also be involved in triggering reversible membrane blebbing allowing leukocytes to migrate and invade through extracellular matrices. Finally, P2X7-mediated membrane blebbing has been proposed as an early step leading to shedding of microvesicles in the microenvironment.

Release of Microvesicles

33Since the discovery that P2X7 is central to the release of the proinflammatory cytokine IL-1β by macrophages, there have been extensive investigations on how this mechanism occurs, since IL-1β belongs to the leaderless secretory protein group lacking the secretory signal necessary for conventional protein secretion through the endoplasmic reticulum route. These studies have shown that IL-1β secretion is instead mainly caused by P2X7 induced nonconventional pathways including microvesicle shedding, exosomes and modified lysosomes. Other studies further showed involvement of P2X7 in microvesicles that release cytokines by fibroblasts and microglia, HIV particles by macrophages and tissue factor by macrophages and DCs.

Release of ROS

34During environmental stress such as ionizing radiation, UV, or heat exposure, increased ROS production mediates oxidative stress, damages cellular structures and initiates cell death. However, low levels of ROS can act as signaling molecules. In phagocytes, ROS are used as bactericides to complete the phagocytosis process. Hence, cells need to control ROS levels tightly in order to meet their physiological needs, while preventing cell death. Production of ROS is mediated mainly by NADPH oxidases (NOXs), and the electron transport chain in mitochondria. During tumor development, oncogenic stimulation, increased metabolic activity and mitochondrial defects lead to increased ROS production forcing cancer cells to increase their antioxidant capacity to prevent cell death. Several reports have shown the induction of ROS production downstream of P2X7 activation [reviewed in]. They show that P2X7-mediated Ca2+ influx leads to activation of kinases that phosphorylate NADPH oxidases (NOXs) to activate the production of ROS. However, there are contradictory reports on the nature of the pathway involved in the phosphorylation of NOXs. In microglial cells, p38 MAPK and PI3K but not ERK1/2 have been shown to mediate ROS production. In macrophages, two studies have shown activation of ERK1/2 downstream of PKC, c-Src, Pyk2 but no involvement of PI3K or p38 MAPK while Noguchi et al. reported activation of the ASK1, p38 MAPK signaling pathway is required for ROS production. Low levels of ATP stimulation increase mitochondrial Ca2+ content leading to hyperpolarization of mitochondrial potential and increased ATP production. In line with these data, P2X7 was shown to drive the expression of glycolytic enzymes leading to increased glycolysis and oxidative phosphorylation that sustains cancer cell growth in the absence of glucose and serum.

Control of P2X7 Localization as a Mean to Modulate P2X7 Function

35P2X7 has been shown to localize in several cellular compartments including the plasma membrane, endoplasmic reticulum (ER), lysosomes, and phagosomes. In human monocytes and lymphocytes, P2X7 was found to be localized mainly intracellularly while differentiation of monocytes into macrophages led to P2X7 localizing to the plasma membrane. In contrast, in mouse microglia and macrophages, P2X7 localizes mainly at the plasma membrane. In cancer cells, Gilbert and colleagues showed that nfP2X7 colocalizes with the ER marker, calreticulin indicating that a misfolded form of the receptor may be retained intracellularly. This was further supported by the relocalization of this form to the plasma membrane upon treatment with small molecule corrector KM11060 that increases the rate of protein secretion. Interestingly, this increased membrane expression was also stimulated by high ATP concentrations (500 µM and above) that suggests that cells may be using ER to plasma membrane localization as a mean to regulate P2X7 functions.

36Palmitoylation of cysteine residues at the hinge of the C-terminal tail was shown to be required for P2X7 to localize to the plasma membrane and associate with lipid rafts. While several reports have confirmed P2X7 interaction with lipid rafts in multiple cell types, the localization of P2X7 in lipid rafts may not be exclusive. Garcia-Marcos et al. have identified two P2X7 pools located in both lipid raft and nonlipid raft membrane compartments. They further showed that the nonlipid raft P2X7 pool can open a nonselective cation channel while the lipid raft P2X7 pool only is able to activate phospholipase A2 (PLA2). Hence, the nature of the lipid content in the membrane surrounding P2X7 receptors can regulate receptor signaling and ultimately its function. Indeed, cholesterol was shown to inhibit P2X7 macropore function while sphingomyelin and 1-palmitoyl-2-oleoyl-sn-glycero-3-phospho-(1’-rac-glycerol) (POPG) were shown to enhance macropore function. Similarly, phosphatidylinositol 4,5-bisphosphate (PIP2) was shown to modulate P2X7 ion channel function. Although no direct interaction was found between P2X7 and PIP2, several residues in the C-terminal tail (R385, K387 and K395) were shown to be involved in PIP2 regulation. The I568N polymorphism also located in the P2X7 C-terminal tail was shown to impair P2X7 trafficking to the membrane while the H155Y polymorphism increased P2X7 localization to the plasma membrane.

37Evidence from several groups points to the existence of signaling cassettes located in the C-terminal tail of P2X7 which supports P2X7 trafficking to the plasma membrane. Indeed, Lenertz have shown the presence of an ER retention/retrieval cassette in the P2X7 C-terminal tail near R576. This cassette allows P2X7 monomers to be retained in the ER while being assembled into trimers. P2X7 channels are then addressed to the plasma membrane through the secretory pathway. A similar mechanism has already been reported for other multimeric membrane receptors such as the N-methyl-D-aspartate (NMDA), glutamate receptor and the γ-aminobutyric acid type B (GABAB) receptor. The section of P2X7 C-terminal tail overlapping with that cassette also was found to bind to phospholipids as well as LPS in a macrophage cell line thereby modulating receptor membrane localization and its capacity to signal through the MAP Kinase and NF-κB pathway.

The Function and Expression of P2X7 Across Cancer Types

38The presence of P2X7 has been shown in a large number of studies using tumor-derived biopsies, cell lines, xenografts and syngenic murine models across multiple and diverse cancer types. The majority of these publications, which demonstrate the presence of P2X7, have not directly assessed functionality of the P2X7 macropore. Given the high concentration of ATP in solid tumors, present at levels capable of inducing P2X7 pore activation and thereby death, it is unlikely that cells expressing fully functional P2X7 could survive in the TME over extended time periods. Therefore, it is probable that cells expressing P2X7 within the TME need to express P2X7 predominantly in a form where pore activity is attenuated. Despite this attenuation of pore function, it is clear from a number of studies that the P2X7 expressed in these cancer cells retains significant signaling functionality and the ability to drive the formation, survival and metastatic potential of tumor cells as previously reported.

39The P2X7 receptor is expressed on a number of cancer types including, but not limited to prostate, lung, kidney, colorectal, gastric, breast, cutaneous squamous-cell and basal-cell carcinomas, melanoma, leukemia, neuroblastoma, glioma, ovarian, cervical, bladder, papillary thyroid, pancreatic and bone cancer. This includes nfP2X7. The key data demonstrating the expression and function of P2X7 on these cancer types is discussed below while Table 2 provides a list of references per cancer type.

Prostate Cancer

40In an immunohistochemistry (IHC) study looking at 116 prostate cancer biopsies using an affinity-purified polyclonal antibody to the E200 epitope of P2X7 (supplied by Biosceptre), P2X7, in a nonpore functioning form, was identified in all malignant samples regardless of their stage or the age of the patient. This was confirmed using a mouse monoclonal antibody (BPM09, supplied by Biosceptre). In another study, increased expression of nfP2X7 was observed as prostate disease progressed. P2X7 expression by IHC also was compared with the levels of prostate-specific antigen (PSA) in 174 prostate cancer biopsies. Increased nfP2X7 staining correlated with increased PSA levels indicating that P2X7 may provide a diagnostic biomarker candidate for early prostate cancer. These results were consistent with those of a separate study demonstrating increased P2X7 mRNA and protein expression in prostate tumor samples compared with normal tissue. Increased P2X7 expression correlates with expression of epidermal growth factor receptor (EGFR) and estrogen receptor (ER)α, which are well known drivers of cancer cell proliferation, suggesting that P2X7 might cooperate with these receptors to promote cell proliferation. These observations support the proposed role for P2X7 in cancer cell survival and proliferation. Indeed, functional P2X7 was shown to drive invasion and metastasis of prostate cancer cell lines stimulated by extracellular ATP.

Lung Cancer

41In a study analyzing P2X7 mRNA expression in 26 patients with nonsmall cell lung cancer (NSCLC), compared with 21 patients with chronic obstructive pulmonary disease (COPD) without signs of malignancy, higher P2X7 expression was observed in bronchoalveolar lavage derived cells of tumors with distant metastases. P2X7 is also expressed in human NSCLC cell lines including A549, PC9 and H292 cells but not in the nonmalignant bronchial epithelial cells BEAS-2B. In H292 cells, inhibition or down-regulation of P2X7 abrogated TGF-β1 induced migration and actin remodeling. P2X7 is required for TGF-β1-induced exocytosis of ATP that then acts as a paracrine factor in lung cancer cell model. Overall, these data suggest a role for P2X7 in promoting invasion and the development of aggressive forms of lung cancer.

Kidney Cancer

42Clear-cell renal cell carcinoma (ccRCC) is the most common form of renal cell carcinoma. In a study analyzing 273 ccRCC patients by IHC, P2X7 expression was correlated with the clinicopathologic features and cancer-specific survival (CSS). Although intratumoral P2X7 expression was lower than peritumoral P2X7 expression, those patients with high intratumoral P2X7 expression had a worse prognosis. Overall, these data suggest that intratumoral P2X7 is involved in the progression of ccRCC. In contrast, the significant P2X7 expression found in peritumoral tissues may reflect P2X7 involvement in the TME. Further exploration of the cell type expressing P2X7 in ccRCC TME is now needed to better understand the nature of that involvement.

Colorectal and Gastric Cancer

43P2X7 protein was identified by IHC with staining distributed throughout the cell in a small number of normal colorectal epithelia and colon adenocarcinomas. Qian et al. demonstrated that high P2X7 expression correlated with tumor size, lymph nodes metastasis, TNM stage and was also associated with poor overall survival in a cohort of 116 colon carcinoma. These contradicting results suggest that there may be subtypes of colorectal cancer characterized by their level of P2X7 expression. Indeed, Zhang et al. analyzed normal tissue and colorectal cancer samples from 97 patients and found both P2X7 high and P2X7 low populations with P2X7 high population having increased metastasis and reduced survival. Both P2X7 and nfP2X7 were identified in human colorectal cancer epithelium although the nfP2X7 expression was much more significant. While nfP2X7 was identified in the human HT-29 and Colo-205 colon cancer cell lines, other reports have shown P2X7 expression in human HCT8, Caco-2, Colo-205, and murine MCA38 colon cancer cell lines and the latter cell line was found to possess functional P2X7 macropore. Analysis of P2X7 expression in 156 gastric cancers corelated P2X7 expression with tumor burden and poor survival suggesting that P2X7 may be involved in the progression of gastric cancer.

Breast Cancer

44An IHC study analyzing nfP2X7 expression in 40 breast tumors of diverse histological subtypes demonstrated that nfP2X7 expression was absent in normal and hyperplastic breast epithelial samples while in situ or invasive lobular or ductal carcinoma expressed high levels of nfP2X7. Tumor cells from invasive carcinomas showed membrane staining as opposed to intracellular staining in in situ carcinomas. Therefore, nfP2X7 membrane staining may be stage-specific and nfP2X7 expression levels may help to distinguish between different stages of breast cancer. P2X7 mRNA and protein also were upregulated under hypoxic conditions in the noninvasive breast cancer cell line MCF-7 which has a nonfunctional P2X7 pore. In contrast, two independent studies looking at P2X7 expression showed a reduction of P2X7 staining in breast cancer versus normal tissue. The antibodies used in these studies were raised against the C-terminal tail of the receptor and are therefore likely to mainly detect P2X7 variant A. These antibodies are unable to discriminate between functional P2X7 and nfP2X7. Hence, while discrepancies exist for the expression of P2X7 variant A in breast cancer, nfP2X7 appears to be specifically upregulated at the surface of breast cancer cells. Tan et al. reported higher P2X7 expression levels in the breast cancer tissues when compared with normal breast tissue. Furthermore, a positive correlation was observed between P2X7 expression and the estrogen receptor (ER)+ by qRT-PCR, western blot and immunohistochemistry analysis.

Cutaneous Squamous-Cell and Basal-Cell Carcinomas

45P2X7 is highly expressed both in nodular basal cell carcinomas (BCC) and in infiltrative BCC cells where it was shown to be present in some tumor cell nuclei. P2X7 expression was also found in the human squamous cell carcinoma (SCC) cell line A431,. nfP2X7 protein also was upregulated in 25 SCC compared to 20 keratoacanthomas (KA). Using an affinity purified sheep polyclonal antibody to nfP2X7, systemic treatment of advanced cat SCC showed decreased lesion size. In a more recent study, the presence of nfP2X7 was shown in BCC and antibodies specific for nfP2X7 rather than fully functional P2X7 were shown to be a safe treatment for BCC with 65% of patients showing reduced lesion area, 20% showing stable tumor size and 15% with increased lesion area. Overall, these data support the targeting of nfP2X7 in BCC and SCC.

Melanoma

46In an IHC study looking at 80 human melanoma biopsies, nfP2X7 protein was overexpressed in malignant tissues when compared with nonmalignant samples. P2X7 upregulation was also observed on keratinocytes of the epidermis surrounding the tumor. A study analyzing P2X7 in 14 human melanoma biopsies confirmed the upregulation of P2X7 in melanoma with over 75% of samples staining positively. Upregulation of P2X7 in melanoma samples was confirmed in cell lines at the mRNA level. Indeed, whole genome microarray screening of the NCI-60 cancer cell line panel has shown full length P2X7 upregulation as a hallmark of melanoma cell lines. The human melanoma cell line A375 was found to express P2X7 variant A and to have a functional large pore.

Leukemia

47P2X7 is upregulated in T-cell acute lymphoblastic leukemia and in murine erythroleukemia (MEL) cells. In MEL cells, P2X7 was also shown to have a functional macropore. P2X7 was also upregulated in pediatric leukemias as well as in human myeloid leukaemic cell lines F-36P and HL-60. In a separate study, P2X7 mRNA and protein were upregulated in 8 out of 11 cell lines, 69 out of 87 bone marrow mononuclear cell (BMMC) samples from leukemia patients and 9 out of 10 myelodysplastic syndrome (MDS) patients. Furthermore, P2X7 also was significantly upregulated in acute myelogenous leukemia (AML) and acute lymphoblastic leukemia (ALL). P2X7 expression was found to be higher in AML subtypes having poor prognosis. Following standard induction, P2X7 was upregulated in a group with a low remission rate. Increased P2X7 expression was found in lymphocytes from patients with the evolutive form of B-cell chronic lymphocytic leukemia (B-CLL). Furthermore, P2X7 expression correlated with the severity of B-CLL. However, the large molecular weight pore function was not assessed in this study. In a separate study, antibodies targeting P2X7 were shown to bind to the surface of B-CLL cells. While the analysis of P2X7 membrane expression by flow cytometry suggests that the B-CLL populations tested are not fully uniform, data suggest that B-CLL populations with both functional and nonfunctional macropore can be identified. Overall, these data support a role for P2X7 in the progression of leukemia and the development of aggressive forms of the disease.

Neuroblastoma

48In an IHC study, P2X7 was highly expressed in neuroblastoma irrespective of the tumor grade. P2X7 was also expressed in several neuroblastoma cell lines including ACN, GI-CA-N, HTLA-230, GI-ME-N, LAN-5, LAN-1, SK-N-BE-2, and SH-SY-5Y with cell surface staining characterized for at least ACN. P2X7 stimulation in vitro with ATP did not induce apoptosis of neuroblastoma cells but instead stimulated their proliferation via the enhanced secretion of substance P, which suggests that these cells were nonfunctional for P2X7 macropore. In an independent study, P2X7 mRNA expression was analyzed in 131 patients with neuroblastoma. High P2X7 expression correlated with poor prognosis while patients with low P2X7 expression levels had less aggressive tumors.

Glioma

49Both mRNA and protein were detected in human glioma cell lines U-138MG, U-251MG, and M059J. P2X7 was shown to mediate cell death in response to ATP in glioma cells. While U-138 MG and U-251 MG cells appeared to have a nonfunctional P2X7 pore, M059J glioma cells were reported as having functional receptor macropore. P2X7 is also upregulated in mouse GL261 glioma cells. P2X7 was also upregulated in an in vivo model where rats received an intra-striatal injection of C6 glioma cells. In these cells, P2X7 promoted chemotaxis in vitro, which suggests that P2X7 may play a role in the metastasis process of glioma. In a separate study, Gehring et al. showed that high P2X7 expression was a good prognostic factor for glioma radiosensitivity and survival probability. P2X7 was highly upregulated at the mRNA and protein level in tumor tissue as opposed to peritumoral and adjacent normal tissue. P2X7 upregulation was also observed in cancer stem cells from GBM cultured under hypoxic conditions. This evidence supports the potential involvement of P2X7 in cancer stem cells.

Ovarian Cancer

50P2X7 expression was analyzed by IHC in nine human ovarian carcinoma biopsies and compared with ovarian surface epithelium in healthy tissue. P2X7 was highly expressed in both healthy tissue and ovarian carcinoma. P2X7 also was found to be expressed in the human ovarian cancer cell lines SKOV-3 and CAOV-3. Both P2X7 and nfP2X7 were expressed in ovarian cancer tissue.

Cervical Cancer

51IHC analysis of squamous cell cancer of the cervix showed increased nfP2X7-specific membranous staining when compared to normal tissue. In contrast, Li et al. have reported a decreased expression of full length P2X7 in tissues of complex hyperplasia with atypia or endometrial adenocarcinoma compared to normal endometrium, simple hyperplasia or complex hyperplasia tissues.

Bladder Cancer

52Using Protein Pathway Array (PPA) to investigate the expression of 285 proteins and phosphoproteins in bladder urothelial cell carcinoma tissues and adjacent nontumor tissues, Hu et al. reported that expression of P2X7 was an independent factor, favorable for overall survival. Both P2X7 and nfP2X7 were confirmed to be expressed in bladder cancer tissue in separate IHC studies.

Papillary Thyroid Cancer

53P2X7 mRNA was upregulated in 37 human papillary thyroid cancer (PTC) samples when compared with adjacent normal tissue. P2X7 protein upregulation was also confirmed by IHC in all malignant tissues tested including the classical and follicular forms of the disease. Adjacent normal tissue was devoid of P2X7 staining. P2X7 staining was found to be diffuse in the cytoplasm and intense at the cell surface of malignant thyrocytes. P2X7 mRNA and protein was also detected in FB1 and FB2 human thyroid cancer cell lines. In response to ATP, these cells showed a P2X7 dependent release of IL-6, a cytokine associated with aggressiveness of PTC. P2X7 upregulation in PTC was confirmed by IHC in two independent studies. P2X7 upregulation was shown to correlate with tumor growth, capsular infiltration and lymph node metastases. Additional reports showed nfP2X7 expression in PTC tissue. Overall, these studies support a correlation between P2X7 and nfP2X7 expression and the development of aggressive PTC.

Pancreatic Cancer

54P2X7 mRNA and protein was shown to be upregulated in chronic pancreatitis and pancreatic cancer tissue and cell lines in vitro and in vivo. P2X7 large pore functionality was not assessed in these studies. Other reports demonstrated both P2X7 and nfP2X7 expression in pancreatic cancer tissue.

Bone Cancer

55P2X7 was upregulated in osteosarcoma, Ewing sarcoma, chondromyxoid fibroma as well as in bone cancer cell lines such as SaOs-2 and HOS. SaOs-2 cells have a functional P2X7 large pore. Moreover, P2X7 upregulation plays a key role in several malignancies metastasising to the bone that supports an involvement of P2X7 in the host tissue during the metastatic process (reviewed in. P2X7B splice variant was upregulated in osteosarcoma and its expression was associated with cell proliferation.

Therapeutic Approaches Taken to Target P2X7

56Several pharmaceutical organizations have engaged in the development of both small-molecules and biologics directed against P2X7 ( Table 3 ). These developments can be seen in the increasing number of filed patents for P2X7 targeted treatment. Early development of small molecule inhibitors targeted the P2X7 orthosteric site to compete ATP mediated P2X7 activation. However, the lack of specificity of these inhibitors led to the identification and development of several classes of inhibitors that bind to the inter-subunit allosteric pocket preventing ATP induced rotation of each subunit and closure of the turret. Within this inter-subunit allosteric pocket, several point mutants including but not limited to F88A, D92A, F95A, and F103A were identified to play an important role in the mode of action of these inhibitors. Engagement of this allosteric pocket allowed progressive development of antagonists in the low nanomolar range ( Table 2 ) while providing better selectivity for P2X7 against other P2X family members. Initial identification of lead candidates against the inter-subunit allosteric pocket revealed compounds with good activity against human P2X7 but inactive against the rat isoform making pharmacology studies difficult. However, docking of these candidates in the inter-subunit allosteric pocket highlighted the importance of human F95 (L95 in rat P2X7) in developing pi-stacking interactions with inhibitors.

57Several of these small molecules including AZD9056 (AstraZeneca), CE-224,535 (Pfizer), EVT-401 (Evotec), and GSK1482160 (GlaxoSmithKline plc) have entered clinical studies to treat rheumatoid arthritis as well as other inflammatory conditions ( Table 2 ). Although all clinical data are not yet available, no clear benefits to patients have been observed so far. A recent report of an anti-P2X7 bivalent nanobody-Fc with IC50 in the sub-nanomolar range developed by Ablynx (now Sanofi) appear to show promising preclinical efficacy in chronic inflammatory disease models. As reports increasingly highlight the critical role of P2X7 and ATP in tumor biology and its microenvironment, the rationale for targeting P2X7 in cancer in single or combination therapies is becoming increasingly relevant. Indeed, the recent report of the well-tolerated BIL010t, topical anti-P2X7 treatment of BCC (Biosceptre) revealed promising patient outcomes with 65% of patients treated showing reduced lesion area and 20% with stable disease. Assessment of safety and immunogenicity of an anti P2X7 vaccine (BIL06v – Biosceptre) used in patients with advanced solid tumors is ongoing in Australia.

Conclusion

58Since the discovery of P2X7 as a cytotoxic receptor, studies have shown that the role of P2X7 in tumor biology and its microenvironment is much more complex than initially thought. Because of the significant involvement of P2X7 in the diverse mechanisms that drive tumor progression, this receptor is now believed to be of significant value as a target for the development of new cancer therapies. Preclinical and clinical evidence of P2X7-targeted therapeutics demonstrate the potential for these candidates as innovative cancer therapies. Furthermore, the interplay between the activities of P2X7 in tumor cell biology and antitumor immune responses indicates that P2X7 targeted therapies could also be of significant value when used in combination therapies. Therefore, additional studies, to better link the molecular mechanisms associated with P2X7 activation, signaling and cancer development, are now needed to drive highly innovative, safe and effective first in class therapeutics into the clinic.

Author Contributions

59Conception and design: RL, SM, EA, and FV. Writing, review, and/or revision of the manuscript: RL, EA, CH, MP, JB, FV, and SM.

Funding

60CH and MP, together with Biopsceptre (UK) Limited, have received a CASE Award from the UK Research Council [Biotechnology and Biological Sciences Research Council (BBSRC) (Reference No. BB/M009513/1)] to support a Doctoral Training Partnership. Funder role: Function of P2X7 in healthy and diseased human skin.

61EA is supported by the Italian Association for Cancer Research, IG grant IG22837. Funder role: support for the investigation of the purinergic-adenosinergic axis in inflammation leading to colon cancer development.

62FV is supported by the following grants:

63- Italian Association for Cancer Research, IG grant 22883. Funder role: support for the investigation of repurposing purinergic signalling for cancer therapy.

64- Italian Association for Cancer Research IG grant n.18581. Funder role: support for the investigation of the role of the P2X7 receptor in reprogramming cancer cell metabolism.

65- European Commission, Grant EU COST BM1406. Funder role: support for exchange of young investigators between laboratories involved in the investigation of P2X7 role in immune response.

66- Royal Society Exchange Fellowship IES\R3\170196. Funder role: support for the exchange of investigators involved in the study of P2X7-dependent microvesicle shedding from mononuclear cells.

67- Projects of National Interest (PRIN) Ministry of Education of Italy, grant n. 20178YTNWC. Funder role: support for investigation of the mechanism responsible for P2X7 receptor-mediated release of pro-inflammatory cytokines from mononuclear phagocytes.

Conflict of Interest

68RL is an employee of Biosceptre (UK) Ltd.; JB is an employee of Biosceptre international Ltd.,; SM was an employee of Biosceptre (UK) Ltd; FV serves as a member of Biosceptre Scientific Advisory Board. Biosceptre is a company commercializing nfP2X7 targeted therapies. CH and MP have received a CASE Award together with Biosceptre (UK) Limited to support a Doctoral Training Partnership from the UK Research Council [Biotechnology and Biological Sciences Research Council (BBSRC) (Reference No. BB/M009513/1)].

69The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest..

References 385

1.
Abbracchio M. P. Burnstock G. (1994 ). Purinoceptors: are there families of P2X and P2Y purinoceptors? Pharmacol. Ther. 64 (3), 445–475.
Not in our library10.1016/0163-7258(94)00048-4
2.
Adinolfi E. Melchiorri L. Falzoni S. Chiozzi P. Morelli A. Tieghi A. (2002 ). P2X7 receptor expression in evolutive and indolent forms of chronic B lymphocytic leukemia. Blood 99 (2), 706–708.
Not in our library10.1182/blood.v99.2.706
3.
Adinolfi E. Kim M. Young M. T. Di Virgilio F. Surprenant A. (2003 ). Tyrosine phosphorylation of HSP90 within the P2X7 receptor complex negatively regulates P2X7 receptors. J. Biol. Chem. 278 (39), 37344–37351.
Not in our library10.1074/jbc.m301508200
4.
Adinolfi E. Callegari M. G. Ferrari D. Bolognesi C. Minelli M. Wieckowski M. R. (2005 ). Basal activation of the P2X7 ATP receptor elevates mitochondrial calcium and potential, increases cellular ATP levels, and promotes serum-independent growth. Mol. Biol. Cell 16 (7), 3260–3272.
Not in our library10.1091/mbc.e04-11-1025
5.
Adinolfi E. Callegari M. G. Cirillo M. Pinton P. Giorgi C. Cavagna D. (2009 ). Expression of the P2X7 receptor increases the Ca2+ content of the endoplasmic reticulum, activates NFATc1, and protects from apoptosis. J. Biol. Chem. 284 (15), 10120–10128.
Not in our library10.1074/jbc.m805805200
6.
Adinolfi E. Cirillo M. Woltersdorf R. Falzoni S. Chiozzi P. Pellegatti P. (2010 ). Trophic activity of a naturally occurring truncated isoform of the P2X7 receptor. FASEB J. 24 (9), 3393–3404.
Not in our library10.1096/fj.09-153601
7.
Adinolfi E. Raffaghello L. Giuliani A. L. Cavazzini L. Capece M. Chiozzi P. (2012 a). Expression of P2X7 receptor increases in vivo tumor growth. Cancer Res. 72 (12), 2957–2969.
Not in our library10.1158/0008-5472.can-11-1947
8.
Adinolfi E. Amoroso F. Giuliani A. L. (2012 b). P2X7 Receptor Function in Bone-Related Cancer. J. Osteoporos 2012, 637863.
Not in our library10.1155/2012/637863
9.
Adinolfi E. Capece M. Franceschini A. Falzoni S. Giuliani A. L. Rotondo A. (2015 a). Accelerated tumor progression in mice lacking the ATP receptor P2X7. Cancer Res. 75 (4), 635–644.
Not in our library10.1158/0008-5472.can-14-1259
10.
Adinolfi E. Capece M. Amoroso F. De Marchi E. Franceschini A. (2015 b). Emerging roles of P2X receptors in cancer. Curr. Med. Chem. 22 (7), 878–890.
Not in our library10.2174/0929867321666141012172913
11.
Adinolfi E. Giuliani A. L. De Marchi E. Pegoraro A. Orioli E. Di Virgilio F. (2018 ). The P2X7 receptor: A main player in inflammation. Biochem. Pharmacol. 151, 234–244.
Not in our library10.1016/j.bcp.2017.12.021
12.
Adinolfi E. De Marchi E. Orioli E. Pegoraro A. Di Virgilio F. (2019 ). Role of the P2X7 receptor in tumor-associated inflammation. Curr. Opin. Pharmacol. 47, 59–64.
Not in our library10.1016/j.coph.2019.02.012
13.
Adriouch S. Bannas P. Schwarz N. Fliegert R. Guse A. H. Seman M. (2008 ). ADP-ribosylation at R125 gates the P2X7 ion channel by presenting a covalent ligand to its nucleotide binding site. FASEB J. 22 (3), 861–869.
Not in our library10.1096/fj.07-9294com
14.
Agrawal A. Henriksen Z. Syberg S. Petersen S. Aslan D. Solgaard M. (2017 ). P2X7Rs are involved in cell death, growth and cellular signaling in primary human osteoblasts. Bone 95, 91–101.
Not in our library10.1016/j.bone.2016.11.011
15.
Allard B. Longhi M. S. Robson S. C. Stagg J. (2017 ). The ectonucleotidases CD39 and CD73: Novel checkpoint inhibitor targets. Immunol. Rev. 276 (1), 121–144.
Not in our library10.1111/imr.12528
16.
Allsopp R. C. Dayl S. Schmid R. Evans R. J. (2017 ). Unique residues in the ATP gated human P2X7 receptor define a novel allosteric binding pocket for the selective antagonist AZ10606120. Sci. Rep. 7 (1), 725.
Not in our library10.1038/s41598-017-00732-5
17.
Allsopp R. C. Dayl S. Bin Dayel A. Schmid R. Evans R. J. (2018 ). Mapping the Allosteric Action of Antagonists A740003 and A438079 Reveals a Role for the Left Flipper in Ligand Sensitivity at P2X7 Receptors. Mol. Pharmacol. 93 (5), 553–562.
Not in our library10.1124/mol.117.111021
18.
Alqallaf S. M. Evans B. A. Kidd E. J. (2009 ). Atypical P2X receptor pharmacology in two human osteoblast-like cell lines. Br. J. Pharmacol. 156 (7), 1124–1135.
Not in our library10.1111/j.1476-5381.2009.00119.x
19.
Amoroso F. Falzoni S. Adinolfi E. Ferrari D. Di Virgilio F. (2012 ). The P2X7 receptor is a key modulator of aerobic glycolysis. Cell Death Dis. 3, e370.
Not in our library10.1038/cddis.2012.105
20.
Amoroso F. Capece M. Rotondo A. Cangelosi D. Ferracin M. Franceschini A. (2015 ). The P2X7 receptor is a key modulator of the PI3K/GSK3beta/VEGF signaling network: evidence in experimental neuroblastoma. Oncogene 34 (41), 5240–5251.
Not in our library10.1038/onc.2014.444
21.
Amoroso F. Salaro E. Falzoni S. Chiozzi P. Giuliani A. L. Cavallesco G. (2016 ). P2X7 targeting inhibits growth of human mesothelioma. Oncotarget 7 (31), 49664–49676.
Not in our library10.18632/oncotarget.10430
22.
Amstrup J. Novak I. (2003 ). P2X7 receptor activates extracellular signal-regulated kinases ERK1 and ERK2 independently of Ca2+ influx. Biochem. J. 374 (Pt 1), 51–61.
Not in our library10.1042/bj20030585
23.
Andrei C. Margiocco P. Poggi A. Lotti L. V. Torrisi M. R. Rubartelli A. (2004 ). Phospholipases C and A2 control lysosome-mediated IL-1 beta secretion: Implications for inflammatory processes. Proc. Natl. Acad. Sci. U. S. A. 101 (26), 9745–9750.
Not in our library10.1073/pnas.0308558101
24.
Antonioli L. Blandizzi C. Pacher P. Hasko G. (2013 ). Immunity, inflammation and cancer: a leading role for adenosine. Nat. Rev. Cancer 13 (12), 842–857.
Not in our library10.1038/nrc3613
25.
Arulkumaran N. Unwin R. J. Tam F. W. (2011 ). A potential therapeutic role for P2X7 receptor (P2X7R) antagonists in the treatment of inflammatory diseases. Expert Opin. Invest. Drugs 20 (7), 897–915.
Not in our library10.1517/13543784.2011.578068
26.
Aswad F. Kawamura H. Dennert G. (2005 ). High sensitivity of CD4+CD25+ regulatory T cells to extracellular metabolites nicotinamide adenine dinucleotide and ATP: a role for P2X7 receptors. J. Immunol. 175 (5), 3075–383.
Not in our library10.4049/jimmunol.175.5.3075
27.
Atarashi K. Nishimura J. Shima T. Umesaki Y. Yamamoto M. Onoue M. (2008 ). ATP drives lamina propria T(H)17 cell differentiation. Nature 455 (7214), 808–812.
Not in our library10.1038/nature07240
28.
Babelova A. Moreth K. Tsalastra-Greul W. Zeng-Brouwers J. Eickelberg O. Young M. F. (2009 ). Biglycan, a danger signal that activates the NLRP3 inflammasome via toll-like and P2X receptors. J. Biol. Chem. 284 (36), 24035–24048.
Not in our library10.1074/jbc.m109.014266
29.
Bae J. Y. Lee S. W. Shin Y. H. Lee J. H. Jahng J. W. Park K. (2017 ). P2X7 receptor and NLRP3 inflammasome activation in head and neck cancer. Oncotarget. 8 (30), 48972–48982.
Not in our library10.18632/oncotarget.16903
30.
Bailis W. Shyer J. A. Zhao J. Canaveras J. C. G. Al Khazal F. J. Qu R. (2019 ). Distinct modes of mitochondrial metabolism uncouple T cell differentiation and function. Nature 571 (7765), 403–407.
Not in our library10.1038/s41586-019-1311-3
31.
Bannas P. Adriouch S. Kahl S. Braasch F. Haag F. Koch-Nolte F. (2005 ). Activity and specificity of toxin-related mouse T cell ecto-ADP-ribosyltransferase ART2.2 depends on its association with lipid rafts. Blood 105 (9), 3663–3670.
Not in our library10.1182/blood-2004-08-3325
32.
Barbera-Cremades M. Baroja-Mazo A. Gomez A. I. Machado F. Di Virgilio F. Pelegrin P. (2012 ). P2X7 receptor-stimulation causes fever via PGE2 and IL-1beta release. FASEB J. 26 (7), 2951–2962.
Not in our library10.1096/fj.12-205765
33.
Barden J. A. Sluyter R. Gu B. J. Wiley J. S. (2003 ). Specific detection of non-functional human P2X(7) receptors in HEK293 cells and B-lymphocytes. FEBS Lett. 538 (1-3), 159–162.
Not in our library10.1016/s0014-5793(03)00172-8
34.
Barden J. Gidley-Baird A. Armstrong A. Bean P. Pilkington G. Sempf F. (2009 ). Abstract #LB-153: Evaluation of non-functional P2X7 receptor as a potential pan cancer therapeutic and diagnostic target. Cancer Res. 69 (9).
Not in our library
35.
Barden J. A. Yuksel A. Pedersten J. Danieletto S. Delprado W. (2014 ). Non-Functional P2X7: A Novel and Ubiquitous Target in Human Cancer. J. Clin. Cell Immunol. 5 (4), 237.
Not in our library10.4172/2155-9899.1000237
36.
Barden J. A. Gidley-Baird A. Teh L. C. Rajasekariah G. H. Pedersen J. Christensen N. I. (2016 ). Therapeutic Targeting of the Cancer-Specific Cell Surface Biomarker nfP2X7. J. Clin. Cell. Immunol. 7 (3), 432.
Not in our library10.4172/2155-9899.1000432
37.
Baricordi O. R. Ferrari D. Melchiorri L. Chiozzi P. Hanau S. Chiari E. (1996 ). An ATP-activated channel is involved in mitogenic stimulation of human T lymphocytes. Blood 87 (2), 682–690.
Not in our library10.1182/blood.v87.2.682.bloodjournal872682
38.
Baricordi O. R. Melchiorri L. Adinolfi E. Falzoni S. Chiozzi P. Buell G. (1999 ). Increased proliferation rate of lymphoid cells transfected with the P2X(7) ATP receptor. J. Biol. Chem. 274 (47), 33206–33208.
Not in our library10.1074/jbc.274.47.33206
39.
Baroni M. Pizzirani C. Pinotti M. Ferrari D. Adinolfi E. Calzavarini S. (2007 ). Stimulation of P2 (P2X7) receptors in human dendritic cells induces the release of tissue factor-bearing microparticles. FASEB J. 21 (8), 1926–1933.
Not in our library10.1096/fj.06-7238com
40.
Barth K. Weinhold K. Guenther A. Young M. T. Schnittler H. Kasper M. (2007 ). Caveolin-1 influences P2X7 receptor expression and localization in mouse lung alveolar epithelial cells. FEBS J. 274 (12), 3021–3033.
Not in our library10.1111/j.1742-4658.2007.05830.x
41.
Baudelet D. Lipka E. Millet R. Ghinet A. (2015 ). Involvement of the P2X7 purinergic receptor in inflammation: an update of antagonists series since 2009 and their promising therapeutic potential. Curr. Med. Chem. 22 (6), 713–729.
Not in our library10.2174/0929867322666141212120926
42.
Beldi G. Wu Y. Banz Y. Nowak M. Miller L. Enjyoji K. (2008 ). Natural killer T cell dysfunction in CD39-null mice protects against concanavalin A-induced hepatitis. Hepatology 48 (3), 841–852.
Not in our library10.1002/hep.22401
43.
Benzaquen J. Heeke S. Janho Dit Hreich S. Douguet L. Marquette C. H. Hofman P. (2019 ). Alternative splicing of P2RX7 pre-messenger RNA in health and diseases: Myth or reality? BioMed. J. 42 (3), 141–154.
Not in our library10.1016/j.bj.2019.05.007
44.
Bergamin L. S. Capece M. Salaro E. Sarti A. C. Falzoni S. Pereira M. S. L. (2019 ). Role of the P2X7 receptor in in vitro and in vivo glioma tumor growth. Oncotarget 10 (47), 4840–4856.
Not in our library10.18632/oncotarget.27106
45.
Bhattacharya A. Wang Q. Ao H. Shoblock J. R. Lord B. Aluisio L. (2013 ). Pharmacological characterization of a novel centrally permeable P2X7 receptor antagonist: JNJ-47965567. Br. J. Pharmacol. 170 (3), 624–640.
Not in our library10.1111/bph.12314
46.
P2X7 Integrates PI3K/AKT and AMPK-PRAS40-mTOR Signaling Pathways to Mediate Tumor Cell Death · 2013
No notice
47.
Bianchi G. Vuerich M. Pellegatti P. Marimpietri D. Emionite L. Marigo I. (2014 ). ATP/P2X7 axis modulates myeloid-derived suppressor cell functions in neuroblastoma microenvironment. Cell Death Dis. 5, e1135.
Not in our library10.1038/cddis.2014.109
48.
Bianco F. Pravettoni E. Colombo A. Schenk U. Moller T. Matteoli M. (2005 ). Astrocyte-derived ATP induces vesicle shedding and IL-1 beta release from microglia. J. Immunol. 174 (11), 7268–7277.
Not in our library10.4049/jimmunol.174.11.7268
49.
Bianco F. Ceruti S. Colombo A. Fumagalli M. Ferrari D. Pizzirani C. (2006 ). A role for P2X7 in microglial proliferation. J. Neurochem. 99 (3), 745–758.
Not in our library10.1111/j.1471-4159.2006.04101.x
50.
Bianco F. Perrotta C. Novellino L. Francolini M. Riganti L. Menna E. (2009 ). Acid sphingomyelinase activity triggers microparticle release from glial cells. EMBO J. 28 (8), 1043–1054.
Not in our library10.1038/emboj.2009.45
51.
Bin Dayel A. Evans R. J. Schmid R. (2019 ). Mapping the Site of Action of Human P2X7 Receptor Antagonists AZ11645373, Brilliant Blue G, KN-62, Calmidazolium, and ZINC58368839 to the Intersubunit Allosteric Pocket. Mol. Pharmacol. 96 (3), 355–363.
Not in our library10.1124/mol.119.116715
52.
Boldt W. Klapperstuck M. Buttner C. Sadtler S. Schmalzing G. Markwardt F. (2003 ). Glu496Ala polymorphism of human P2X7 receptor does not affect its electrophysiological phenotype. Am. J. Physiol. Cell Physiol. 284 (3), C749–C756.
Not in our library10.1152/ajpcell.00042.2002
53.
Borges da Silva H. Beura L. K. Wang H. Hanse E. A. Gore R. Scott M. C. (2018 ). The purinergic receptor P2RX7 directs metabolic fitness of long-lived memory CD8(+) T cells. Nature 559 (7713), 264–268.
Not in our library10.1038/s41586-018-0282-0
54.
Bos J. L. Rehmann H. Wittinghofer A. (2007 ). GEFs and GAPs: critical elements in the control of small G proteins. Cell 129 (5), 865–877.
Not in our library10.1016/j.cell.2007.05.018
55.
Boumechache M. Masin M. Edwardson J. M. Gorecki D. C. Murrell-Lagnado R. (2009 ). Analysis of assembly and trafficking of native P2X4 and P2X7 receptor complexes in rodent immune cells. J. Biol. Chem. 284 (20), 13446–13454.
Not in our library10.1074/jbc.m901255200
56.
Bradford M. D. Soltoff S. P. (2002 ). P2X7 receptors activate protein kinase D and p42/p44 mitogen-activated protein kinase (MAPK) downstream of protein kinase C. Biochem. J. 366 (Pt 3), 745–755.
Not in our library10.1042/bj20020358
57.
Bradley H. J. Baldwin J. M. Goli G. R. Johnson B. Zou J. Sivaprasadarao A. (2011 ). Residues 155 and 348 contribute to the determination of P2X7 receptor function via distinct mechanisms revealed by single-nucleotide polymorphisms. J. Biol. Chem. 286 (10), 8176–8187.
Not in our library10.1074/jbc.m110.211284
58.
Brake A. J. Wagenbach M. J. Julius D. (1994 ). New structural motif for ligand-gated ion channels defined by an ionotropic ATP receptor. Nature 371 (6497), 519–523.
Not in our library10.1038/371519a0
59.
Buell G. N. Talabot F. Gos A. Lorenz J. Lai E. Morris M. A. (1998 a). Gene structure and chromosomal localization of the human P2X7 receptor. Recept. Channels 5 (6), 347–354.
Not in our library
60.
Buell G. Chessell I. P. Michel A. D. Collo G. Salazzo M. Herren S. (1998 b). Blockade of human P2X7 receptor function with a monoclonal antibody. Blood 92 (10), 3521–3528.
Not in our library10.1182/blood.v92.10.3521
61.
Burnstock G. (2006 ). Purinergic signalling. Br. J. Pharmacol. 147 Suppl 1, S172–S181.
Not in our library10.1038/sj.bjp.0706429
62.
Burnstock G. (2014 ). Purinergic signalling: from discovery to current developments. Exp. Physiol. 99 (1), 16–34.
Not in our library10.1113/expphysiol.2013.071951
63.
Cabrini G. Falzoni S. Forchap S. L. Pellegatti P. Balboni A. Agostini P. (2005 ). A His-155 to Tyr polymorphism confers gain-of-function to the human P2X7 receptor of human leukemic lymphocytes. J. Immunol. 175 (1), 82–89.
Not in our library10.4049/jimmunol.175.1.82
64.
Calik I. Calik M. Sarikaya B. Ozercan I. H. Arslan R. Artas G. (2020 ). P2X7R as an independent prognostic indicator in gastric cancer. Bosn. J. Basic Med. Sci. 20 (2), 188–196.
Not in our library10.17305/bjbms.2020.4620
65.
Caseley E. A. Muench S. P. Baldwin S. A. Simmons K. Fishwick C. W. Jiang L. H. (2015 ). Docking of competitive inhibitors to the P2X7 receptor family reveals key differences responsible for changes in response between rat and human. Bioorg. Med. Chem. Lett. 25 (16), 3164–3167.
Not in our library10.1016/j.bmcl.2015.06.001
66.
Chadet S. Jelassi B. Wannous R. Angoulvant D. Chevalier S. Besson P. (2014 ). The activation of P2Y2 receptors increases MCF-7 breast cancer cells migration through the MEK-ERK1/2 signalling pathway. Carcinogenesis 35 (6), 1238–1247.
Not in our library10.1093/carcin/bgt493
67.
Chaumont S. Jiang L. H. Penna A. North R. A. Rassendren F. (2004 ). Identification of a trafficking motif involved in the stabilization and polarization of P2X receptors. J. Biol. Chem. 279 (28), 29628–29638.
Not in our library10.1074/jbc.m403940200
68.
Cheewatrakoolpong B. Gilchrest H. Anthes J. C. Greenfeder S. (2005 ). Identification and characterization of splice variants of the human P2X7 ATP channel. Biochem. Biophys. Res. Commun. 332 (1), 17–27.
Not in our library10.1016/j.bbrc.2005.04.087
69.
Chen S. Feng W. Yang X. Yang W. Ru Y. Liao J. (2014 ). Functional expression of P2X family receptors in macrophages is affected by microenvironment in mouse T cell acute lymphoblastic leukemia. Biochem. Biophys. Res. Commun. 446 (4), 1002–1009.
Not in our library10.1016/j.bbrc.2014.03.048
70.
Chessell I. P. Hatcher J. P. Bountra C. Michel A. D. Hughes J. P. Green P. (2005 ). Disruption of the P2X7 purinoceptor gene abolishes chronic inflammatory and neuropathic pain. Pain 114 (3), 386–396.
Not in our library10.1016/j.pain.2005.01.002
71.
Choi J. H. Ji Y. G. Ko J. J. Cho H. J. Lee D. H. (2018 ). Activating P2X7 Receptors Increases Proliferation of Human Pancreatic Cancer Cells via ERK1/2 and JNK. Pancreas 47 (5), 643–651.
Not in our library10.1097/mpa.0000000000001055
72.
Chong J. H. Zheng G. G. Zhu X. F. Guo Y. Wang L. Ma C. H. (2010 a). Abnormal expression of P2X family receptors in Chinese pediatric acute leukemias. Biochem. Biophys. Res. Commun. 391 (1), 498–504.
Not in our library10.1016/j.bbrc.2009.11.087
73.
Chong J. H. Zheng G. G. Ma Y. Y. Zhang H. Y. Nie K. Lin Y. M. (2010 b). The hyposensitive N187D P2X7 mutant promotes malignant progression in nude mice. J. Biol. Chem. 285 (46), 36179–36187.
Not in our library10.1074/jbc.m110.128488
74.
Cockcroft S. Gomperts B. D. (1979 ). ATP induces nucleotide permeability in rat mast cells. Nature 279 (5713), 541–542.
Not in our library10.1038/279541a0
75.
Coddou C. Yan Z. Obsil T. Huidobro-Toro J. P. Stojilkovic S. S. (2011 ). Activation and regulation of purinergic P2X receptor channels. Pharmacol. Rev. 63 (3), 641–683.
Not in our library10.1124/pr.110.003129
76.
Constantinescu P. Wang B. Kovacevic K. Jalilian I. Bosman G. J. Wiley J. S. (2010 ). P2X7 receptor activation induces cell death and microparticle release in murine erythroleukemia cells. Biochim. Biophys. Acta 1798 (9), 1797–1804.
Not in our library10.1016/j.bbamem.2010.06.002
77.
Costa-Junior H. M. Sarmento Vieira F. Coutinho-Silva R. (2011 ). C terminus of the P2X7 receptor: treasure hunting. Purinerg. Signal 7 (1), 7–19.
Not in our library10.1007/s11302-011-9215-1
78.
Coutinho-Silva R. Stahl L. Raymond M. N. Jungas T. Verbeke P. Burnstock G. (2003 ). Inhibition of chlamydial infectious activity due to P2X7R-dependent phospholipase D activation. Immunity 19 (3), 403–412.
Not in our library10.1016/s1074-7613(03)00235-8
79.
Coutinho-Silva R. Stahl L. Cheung K. K. de Campos N. E. de Oliveira Souza C. Ojcius D. M. (2005 ). P2X and P2Y purinergic receptors on human intestinal epithelial carcinoma cells: effects of extracellular nucleotides on apoptosis and cell proliferation. Am. J. Physiol. Gastrointest. Liver Physiol. 288 (5), G1024–G1035.
Not in our library10.1152/ajpgi.00211.2004
80.
D’Autreaux B. Toledano M. B. (2007 ). ROS as signalling molecules: mechanisms that generate specificity in ROS homeostasis. Nat. Rev. Mol. Cell Biol. 8 (10), 813–824.
Not in our library10.1038/nrm2256
81.
Dagvadorj J. Shimada K. Chen S. Jones H. D. Tumurkhuu G. Zhang W. (2015 ). Lipopolysaccharide Induces Alveolar Macrophage Necrosis via CD14 and the P2X7 Receptor Leading to Interleukin-1alpha Release. Immunity 42 (4), 640–653.
Not in our library10.1016/j.immuni.2015.03.007
82.
Danquah W. Meyer-Schwesinger C. Rissiek B. Pinto C. Serracant-Prat A. Amadi M. (2016 ). Nanobodies that block gating of the P2X7 ion channel ameliorate inflammation. Sci. Transl. Med. 8 (366), 366ra162.
Not in our library10.1126/scitranslmed.aaf8463
83.
Dardano A. Falzoni S. Caraccio N. Polini A. Tognini S. Solini A. (2009 ). 1513A>C polymorphism in the P2X7 receptor gene in patients with papillary thyroid cancer: correlation with histological variants and clinical parameters. J. Clin. Endocrinol. Metab. 94 (2), 695–698.
Not in our library10.1210/jc.2008-1322
84.
de Andrade Mello P. Coutinho-Silva R. Savio L. E. B. (2017 ). Multifaceted Effects of Extracellular Adenosine Triphosphate and Adenosine in the Tumor-Host Interaction and Therapeutic Perspectives. Front. Immunol. 8, 1526.
Not in our library10.3389/fimmu.2017.01526
85.
De Marchi E. Orioli E. Dal Ben D. Adinolfi E. (2016 ). P2X7 Receptor as a Therapeutic Target. Adv. Protein Chem. Struct. Biol. 104, 39–79.
Not in our library10.1016/bs.apcsb.2015.11.004
86.
The P2X7 receptor modulates immune cells infiltration, ectonucleotidases expression and extracellular ATP levels in the tumor microenvironment · 2019
No notice
87.
Macrophage activation and polarization modify P2X7 receptor secretome influencing the inflammatory process · 2016
No notice
88.
Denlinger L. C. Fisette P. L. Sommer J. A. Watters J. J. Prabhu U. Dubyak G. R. (2001 ). Cutting edge: the nucleotide receptor P2X7 contains multiple protein- and lipid-interaction motifs including a potential binding site for bacterial lipopolysaccharide. J. Immunol. 167 (4), 1871–1876.
Not in our library10.4049/jimmunol.167.4.1871
89.
Denlinger L. C. Sommer J. A. Parker K. Gudipaty L. Fisette P. L. Watters J. W. (2003 ). Mutation of a dibasic amino acid motif within the C terminus of the P2X7 nucleotide receptor results in trafficking defects and impaired function. J. Immunol. 171 (3), 1304–1311.
Not in our library10.4049/jimmunol.171.3.1304
90.
Di A. Xiong S. Ye Z. Malireddi R. K. S. Kometani S. Zhong M. (2018 ). The TWIK2 Potassium Efflux Channel in Macrophages Mediates NLRP3 Inflammasome-Induced Inflammation. Immunity 49 (1), 56–65 e4.
Not in our library10.1016/j.immuni.2018.04.032
91.
Di Virgilio F. Adinolfi E. (2017 ). Extracellular purines, purinergic receptors and tumor growth. Oncogene 36 (3), 293–303.
Not in our library10.1038/onc.2016.206
92.
Di Virgilio F. Meyer B. C. Greenberg S. Silverstein S. C. (1988 ). Fc receptor-mediated phagocytosis occurs in macrophages at exceedingly low cytosolic Ca2+ levels. J. Cell Biol. 106 (3), 657–666.
Not in our library10.1083/jcb.106.3.657
93.
Di Virgilio F. Chiozzi P. Falzoni S. Ferrari D. Sanz J. M. Venketaraman V. (1998 ). Cytolytic P2X purinoceptors. Cell Death Differ. 5 (3), 191–199.
Not in our library10.1038/sj.cdd.4400341
94.
Di Virgilio F. Ferrari D. Adinolfi E. (2009 ). P2X(7): a growth-promoting receptor-implications for cancer. Purinerg. Signal 5 (2), 251–256.
Not in our library10.1007/s11302-009-9145-3
95.
Di Virgilio F. Falzoni S. Giuliani A. L. Adinolfi E. (2016 ). P2 receptors in cancer progression and metastatic spreading. Curr. Opin. Pharmacol. 29, 17–25.
Not in our library10.1016/j.coph.2016.05.001
96.
Di Virgilio F. Dal Ben D. Sarti A. C. Giuliani A. L. Falzoni S. (2017 ). The P2X7 Receptor in Infection and Inflammation. Immunity 47 (1), 15–31.
Not in our library10.1016/j.immuni.2017.06.020
97.
Di Virgilio F. Sarti A. C. Falzoni S. De Marchi E. Adinolfi E. (2018 a). Extracellular ATP and P2 purinergic signalling in the tumour microenvironment. Nat. Rev. Cancer 18 (10), 601–618.
Not in our library10.1038/s41568-018-0037-0
98.
Di Virgilio F. Schmalzing G. Markwardt F. (2018 b). The Elusive P2X7 Macropore. Trends Cell Biol. 28 (5), 392–404.
Not in our library10.1016/j.tcb.2018.01.005
99.
Di Virgilio F. Sarti A. C. Grassi F. (2018 c). Modulation of innate and adaptive immunity by P2X ion channels. Curr. Opin. Immunol. 52, 51–59.
Not in our library10.1016/j.coi.2018.03.026
100.
Di Virgilio F. Jiang L. H. Roger S. Falzoni S. Sarti A. C. Vultaggio-Poma V. (2019 ). Structure, function and techniques of investigation of the P2X7 receptor (P2X7R) in mammalian cells. Methods Enzymol. 629, 115–150.
Not in our library10.1016/bs.mie.2019.07.043
101.
Di Virgilio F. (2015 ). P2X receptors and inflammation. Curr. Med. Chem. 22 (7), 866–877.
Not in our library10.2174/0929867322666141210155311
102.
Dinarello C. A. (2002 ). The IL-1 family and inflammatory diseases. Clin. Exp. Rheumatol. 20 (5 Suppl 27), S1–13.
Not in our library
103.
Donnelly-Roberts D. L. Namovic M. T. Han P. Jarvis M. F. (2009 a). Mammalian P2X7 receptor pharmacology: comparison of recombinant mouse, rat and human P2X7 receptors. Br. J. Pharmacol. 157 (7), 1203–1214.
Not in our library10.1111/j.1476-5381.2009.00233.x
104.
Donnelly-Roberts D. L. Namovic M. T. Surber B. Vaidyanathan S. X. Perez-Medrano A. Wang Y. (2009 b). [3H]A-804598 ([3H]2-cyano-1-[(1S)-1-phenylethyl]-3-quinolin-5-ylguanidine) is a novel, potent, and selective antagonist radioligand for P2X7 receptors. Neuropharmacology 56 (1), 223–229.
Not in our library10.1016/j.neuropharm.2008.06.012
105.
Modulation of P2X4/P2X7/Pannexin-1 sensitivity to extracellular ATP via Ivermectin induces a non-apoptotic and inflammatory form of cancer cell death · 2015
No notice
106.
Dubyak G. R. (2007 ). Go it alone no more–P2X7 joins the society of heteromeric ATP-gated receptor channels. Mol. Pharmacol. 72 (6), 1402–1405.
Not in our library10.1124/mol.107.042077
107.
Duplantier A. J. Dombroski M. A. Subramanyam C. Beaulieu A. M. Chang S. P. Gabel C. A. (2011 ). Optimization of the physicochemical and pharmacokinetic attributes in a 6-azauracil series of P2X7 receptor antagonists leading to the discovery of the clinical candidate CE-224,535. Bioorg. Med. Chem. Lett. 21 (12), 3708–3711.
Not in our library10.1016/j.bmcl.2011.04.077
108.
Dupre-Crochet S. Erard M. Nubetae O. (2013 ). ROS production in phagocytes: why, when, and where? J. Leukoc. Biol. 94 (4), 657–670.
Not in our library10.1189/jlb.1012544
109.
Eltzschig H. K. Sitkovsky M. V. Robson S. C. (2012 ). Purinergic signaling during inflammation. N Engl. J. Med. 367 (24), 2322–2333.
Not in our library10.1056/nejmra1205750
110.
Eser A. Colombel J. F. Rutgeerts P. Vermeire S. Vogelsang H. Braddock M. (2015 ). Safety and Efficacy of an Oral Inhibitor of the Purinergic Receptor P2X7 in Adult Patients with Moderately to Severely Active Crohn’s Disease: A Randomized Placebo-controlled, Double-blind, Phase IIa Study. Inflammation Bowel Dis. 21 (10), 2247–2253.
Not in our library10.1097/mib.0000000000000514
111.
Esseltine J. L. Laird D. W. (2016 ). Next-Generation Connexin and Pannexin Cell Biology. Trends Cell Biol. 26 (12), 944–955.
Not in our library10.1016/j.tcb.2016.06.003
112.
Fabbrizio P. Amadio S. Apolloni S. Volonte C. (2017 ). P2X7 Receptor Activation Modulates Autophagy in SOD1-G93A Mouse Microglia. Front. Cell Neurosci. 11, 249.
Not in our library10.3389/fncel.2017.00249
113.
Fang J. Chen X. Zhang L. Chen J. Liang Y. Li X. (2013 ). P2X7R suppression promotes glioma growth through epidermal growth factor receptor signal pathway. Int. J. Biochem. Cell Biol. 45 (6), 1109–1120.
Not in our library10.1016/j.biocel.2013.03.005
114.
Feng Y. H. Li X. Wang L. Zhou L. Gorodeski G. I. (2006 ). A truncated P2X7 receptor variant (P2X7-j) endogenously expressed in cervical cancer cells antagonizes the full-length P2X7 receptor through hetero-oligomerization. J. Biol. Chem. 281 (25), 17228–17237.
Not in our library10.1074/jbc.m602999200
115.
Feng Y. H. Li X. Zeng R. Gorodeski G. I. (2006 ). Endogenously expressed truncated P2X7 receptor lacking the C-terminus is preferentially upregulated in epithelial cancer cells and fails to mediate ligand-induced pore formation and apoptosis. Nucleos. Nucleot. Nucleic Acids 25 (9-11), 1271–1276.
Not in our library10.1080/15257770600890921
116.
Ferrari D. Munerati M. Melchiorri L. Hanau S. di Virgilio F. Baricordi O. R. (1994 ). Responses to extracellular ATP of lymphoblastoid cell lines from Duchenne muscular dystrophy patients. Am. J. Physiol. 267 (4 Pt 1), C886–C892.
Not in our library10.1152/ajpcell.1994.267.4.c886
117.
Ferrari D. Chiozzi P. Falzoni S. Dal Susino M. Collo G. Buell G. (1997 a). ATP-mediated cytotoxicity in microglial cells. Neuropharmacology 36 (9), 1295–1301.
Not in our library10.1016/s0028-3908(97)00137-8
118.
Ferrari D. Chiozzi P. Falzoni S. Dal Susino M. Melchiorri L. Baricordi O. R. (1997 b). Extracellular ATP triggers IL-1 beta release by activating the purinergic P2Z receptor of human macrophages. J. Immunol. 159 (3), 1451–1458.
Not in our library
119.
Ferrari D. La Sala A. Chiozzi P. Morelli A. Falzoni S. Girolomoni G. (2000 ). The P2 purinergic receptors of human dendritic cells: identification and coupling to cytokine release. FASEB J. 14 (15), 2466–2476.
Not in our library10.1096/fj.00-0031com
120.
Ferrari D. Pizzirani C. Adinolfi E. Lemoli R. M. Curti A. Idzko M. (2006 ). The P2X7 receptor: a key player in IL-1 processing and release. J. Immunol. 176 (7), 3877–3883.
Not in our library10.4049/jimmunol.176.7.3877
121.
Figliuolo V. R. Savio L. E. B. Safya H. Nanini H. Bernardazzi C. Abalo A. (2017 ). P2X7 receptor promotes intestinal inflammation in chemically induced colitis and triggers death of mucosal regulatory T cells. Biochim. Biophys. Acta 1863 (6), 1183–1194.
Not in our library10.1016/j.bbadis.2017.03.004
122.
Franceschini A. Capece M. Chiozzi P. Falzoni S. Sanz J. M. Sarti A. C. (2015 ). The P2X7 receptor directly interacts with the NLRP3 inflammasome scaffold protein. FASEB J. 29 (6), 2450–2461.
Not in our library10.1096/fj.14-268714
123.
Galluzzi L. Buque A. Kepp O. Zitvogel L. Kroemer G. (2017 ). Immunogenic cell death in cancer and infectious disease. Nat. Rev. Immunol. 17 (2), 97–111.
Not in our library10.1038/nri.2016.107
124.
Garcia-Marcos M. Perez-Andres E. Tandel S. Fontanils U. Kumps A. Kabre E. (2006 ). Coupling of two pools of P2X7 receptors to distinct intracellular signaling pathways in rat submandibular gland. J. Lipid Res. 47 (4), 705–714.
Not in our library10.1194/jlr.m500408-jlr200
125.
Gartland A. Hipskind R. A. Gallagher J. A. Bowler W. B. (2001 ). Expression of a P2X7 receptor by a subpopulation of human osteoblasts. J. Bone Miner. Res. 16 (5), 846–856.
Not in our library10.1359/jbmr.2001.16.5.846
126.
Gartland A. Skarratt K. K. Hocking L. J. Parsons C. Stokes L. Jorgensen N. R. (2012 ). Polymorphisms in the P2X7 receptor gene are associated with low lumbar spine bone mineral density and accelerated bone loss in post-menopausal women. Eur. J. Hum. Genet. 20 (5), 559–564.
Not in our library10.1038/ejhg.2011.245
127.
Gavin M. A. Rasmussen J. P. Fontenot J. D. Vasta V. Manganiello V. C. Beavo J. A. (2007 ). Foxp3-dependent programme of regulatory T-cell differentiation. Nature 445 (7129), 771–775.
Not in our library10.1038/nature05543
128.
Gehring M. P. Pereira T. C. Zanin R. F. Borges M. C. Braga Filho A. Battastini A. M. (2012 ). P2X7 receptor activation leads to increased cell death in a radiosensitive human glioma cell line. Purinerg. Signal 8 (4), 729–739.
Not in our library10.1007/s11302-012-9319-2
129.
Gehring M. P. Kipper F. Nicoletti N. F. Sperotto N. D. Zanin R. Tamajusuku A. S. (2015 ). P2X7 receptor as predictor gene for glioma radiosensitivity and median survival. Int. J. Biochem. Cell Biol. 68, 92–100.
Not in our library10.1016/j.biocel.2015.09.001
130.
Ghalali A. Wiklund F. Zheng H. Stenius U. Hogberg J. (2014 ). Atorvastatin prevents ATP-driven invasiveness via P2X7 and EHBP1 signaling in PTEN-expressing prostate cancer cells. Carcinogenesis 35 (7), 1547–1555.
Not in our library10.1093/carcin/bgu019
131.
Ghiringhelli F. Apetoh L. Tesniere A. Aymeric L. Ma Y. Ortiz C. (2009 ). Activation of the NLRP3 inflammasome in dendritic cells induces IL-1beta-dependent adaptive immunity against tumors. Nat. Med. 15 (10), 1170–1178.
Not in our library10.1038/nm.2028
132.
Giannuzzo A. Pedersen S. F. Novak I. (2015 ). The P2X7 receptor regulates cell survival, migration and invasion of pancreatic ductal adenocarcinoma cells. Mol. Cancer 14, 203.
Not in our library10.1186/s12943-015-0472-4
133.
Giannuzzo A. Saccomano M. Napp J. Ellegaard M. Alves F. Novak I. (2016 ). Targeting of the P2X7 receptor in pancreatic cancer and stellate cells. Int. J. Cancer 139 (11), 2540–2552.
Not in our library10.1002/ijc.30380
134.
Gidley-Baird A. Barden J. A. (2002 ). Antibodies to non-functional p2x7 receptor diagnosis and treatment of cancers and other conditions. Patent No: WO2003020762A1. Available at: https://patents.google.com/patent/WO2003020762A1/3Den
Not in our library
135.
Gidlof O. Smith J. G. Melander O. Lovkvist H. Hedblad B. Engstrom G. (2012 ). A common missense variant in the ATP receptor P2X7 is associated with reduced risk of cardiovascular events. PloS One 7 (5), e37491.
Not in our library10.1371/journal.pone.0037491
136.
Gilbert S. M. Gidley Baird A. Glazer S. Barden J. A. Glazer A. Teh L. C. (2017 ). A phase I clinical trial demonstrates that nfP2X7 -targeted antibodies provide a novel, safe and tolerable topical therapy for basal cell carcinoma. Br. J. Dermatol. 177 (1), 117–124.
Not in our library10.1111/bjd.15364
137.
ATP in the tumour microenvironment drives expression of nfP2X7, a key mediator of cancer cell survival · 2018
No notice
138.
Giuliani A. L. Colognesi D. Ricco T. Roncato C. Capece M. Amoroso F. (2014 ). Trophic activity of human P2X7 receptor isoforms A and B in osteosarcoma. PloS One 9 (9), e107224.
Not in our library10.1371/journal.pone.0107224
139.
Gomez-Villafuertes R. Garcia-Huerta P. Diaz-Hernandez J. I. Miras-Portugal M. T. (2015 ). PI3K/Akt signaling pathway triggers P2X7 receptor expression as a pro-survival factor of neuroblastoma cells under limiting growth conditions. Sci. Rep. 5, 18417.
Not in our library10.1038/srep18417
140.
Gonnord P. Delarasse C. Auger R. Benihoud K. Prigent M. Cuif M. H. (2009 ). Palmitoylation of the P2X7 receptor, an ATP-gated channel, controls its expression and association with lipid rafts. FASEB J. 23 (3), 795–805.
Not in our library10.1096/fj.08-114637
141.
Gopalakrishnan V. Helmink B. A. Spencer C. N. Reuben A. Wargo J. A. (2018 ). The Influence of the Gut Microbiome on Cancer, Immunity, and Cancer Immunotherapy. Cancer Cell 33 (4), 570–580.
Not in our library10.1016/j.ccell.2018.03.015
142.
Graziano F. Desdouits M. Garzetti L. Podini P. Alfano M. Rubartelli A. (2015 ). Extracellular ATP induces the rapid release of HIV-1 from virus containing compartments of human macrophages. Proc. Natl. Acad. Sci. U. S. A 112 (25), E3265–E3273.
Not in our library10.1073/pnas.1500656112
143.
Greig A. V. Linge C. Healy V. Lim P. Clayton E. Rustin M. H. (2003 ). Expression of purinergic receptors in non-melanoma skin cancers and their functional roles in A431 cells. J. Invest. Dermatol. 121 (2), 315–327.
Not in our library10.1046/j.1523-1747.2003.12379.x
144.
Grol M. W. Pereverzev A. Sims S. M. Dixon S. J. (2013 ). P2 receptor networks regulate signaling duration over a wide dynamic range of ATP concentrations. J. Cell Sci. 126 (Pt 16), 3615–3626.
Not in our library10.1242/jcs.122705
145.
Gu B. J. Wiley J. S. (2006 ). Rapid ATP-induced release of matrix metalloproteinase 9 is mediated by the P2X7 receptor. Blood 107 (12), 4946–4953.
Not in our library10.1182/blood-2005-07-2994
146.
Gu B. J. Wiley J. S. (2018 ). P2X7 as a scavenger receptor for innate phagocytosis in the brain. Br. J. Pharmacol. 175 (22), 4195–4208.
Not in our library10.1111/bph.14470
147.
Gu B. Bendall L. J. Wiley J. S. (1998 ). Adenosine triphosphate-induced shedding of CD23 and L-selectin (CD62L) from lymphocytes is mediated by the same receptor but different metalloproteases. Blood 92 (3), 946–951.
Not in our library10.1182/blood.v92.3.946
148.
Gu B. J. Zhang W. Y. Bendall L. J. Chessell I. P. Buell G. N. Wiley J. S. (2000 ). Expression of P2X(7) purinoceptors on human lymphocytes and monocytes: evidence for nonfunctional P2X(7) receptors. Am. J. Physiol. Cell Physiol. 279 (4), C1189–C1197.
Not in our library10.1152/ajpcell.2000.279.4.c1189
149.
Gu B. J. Zhang W. Worthington R. A. Sluyter R. Dao-Ung P. Petrou S. (2001 ). A Glu-496 to Ala polymorphism leads to loss of function of the human P2X7 receptor. J. Biol. Chem. 276 (14), 11135–11142.
Not in our library10.1074/jbc.m010353200
150.
Gu B. J. Sluyter R. Skarratt K. K. Shemon A. N. Dao-Ung L. P. Fuller S. J. (2004 ). An Arg307 to Gln polymorphism within the ATP-binding site causes loss of function of the human P2X7 receptor. J. Biol. Chem. 279 (30), 31287–31295.
Not in our library10.1074/jbc.m313902200
151.
Gu B. J. Rathsam C. Stokes L. McGeachie A. B. Wiley J. S. (2009 ). Extracellular ATP dissociates nonmuscle myosin from P2X(7) complex: this dissociation regulates P2X(7) pore formation. Am. J. Physiol. Cell Physiol. 297 (2), C430–C439.
Not in our library10.1152/ajpcell.00079.2009
152.
Gu B. J. Saunders B. M. Jursik C. Wiley J. S. (2010 ). The P2X7-nonmuscle myosin membrane complex regulates phagocytosis of nonopsonized particles and bacteria by a pathway attenuated by extracellular ATP. Blood 115 (8), 1621–1631.
Not in our library10.1182/blood-2009-11-251744
153.
Gu L. Q. Li F. Y. Zhao L. Liu Y. Chu Q. Zang X. X. (2010 ). Association of XIAP and P2X7 receptor expression with lymph node metastasis in papillary thyroid carcinoma. Endocrine 38 (2), 276–282.
Not in our library10.1007/s12020-010-9384-7
154.
Gu B. J. Saunders B. M. Petrou S. Wiley J. S. (2011 ). P2X(7) is a scavenger receptor for apoptotic cells in the absence of its ligand, extracellular ATP. J. Immunol. 187 (5), 2365–2375.
Not in our library10.4049/jimmunol.1101178
155.
Gu B. J. Duce J. A. Valova V. A. Wong B. Bush A. I. Petrou S. (2012 ). P2X7 receptor-mediated scavenger activity of mononuclear phagocytes toward non-opsonized particles and apoptotic cells is inhibited by serum glycoproteins but remains active in cerebrospinal fluid. J. Biol. Chem. 287 (21), 17318–17330.
Not in our library10.1074/jbc.m112.340885
156.
Gu B. J. Field J. Dutertre S. Ou A. Kilpatrick T. J. Lechner-Scott J. (2015 ). A rare P2X7 variant Arg307Gln with absent pore formation function protects against neuroinflammation in multiple sclerosis. Hum. Mol. Genet. 24 (19), 5644–5654.
Not in our library10.1093/hmg/ddv278
157.
Gudipaty L. Humphreys B. D. Buell G. Dubyak G. R. (2001 ). Regulation of P2X(7) nucleotide receptor function in human monocytes by extracellular ions and receptor density. Am. J. Physiol. Cell Physiol. 280 (4), C943–C953.
Not in our library10.1152/ajpcell.2001.280.4.c943
158.
Guerra A. N. Gavala M. L. Chung H. S. Bertics P. J. (2007 ). Nucleotide receptor signalling and the generation of reactive oxygen species. Purinerg. Signal 3 (1-2), 39–51.
Not in our library10.1007/s11302-006-9035-x
159.
Gulbransen B. D. Bashashati M. Hirota S. A. Gui X. Roberts J. A. MacDonald J. A. (2012 ). Activation of neuronal P2X7 receptor-pannexin-1 mediates death of enteric neurons during colitis. Nat. Med. 18 (4), 600–604.
Not in our library10.1038/nm.2679
160.
Gunosewoyo H. Kassiou M. (2010 ). P2X purinergic receptor ligands: recently patented compounds. Expert Opin. Ther. Pat. 20 (5), 625–646.
Not in our library10.1517/13543771003702424
161.
Guo C. Masin M. Qureshi O. S. Murrell-Lagnado R. D. (2007 ). Evidence for functional P2X4/P2X7 heteromeric receptors. Mol. Pharmacol. 72 (6), 1447–1456.
Not in our library10.1124/mol.107.035980
162.
Gutierrez-Martin Y. Bustillo D. Gomez-Villafuertes R. Sanchez-Nogueiro J. Torregrosa-Hetland C. Binz T. (2011 ). P2X7 receptors trigger ATP exocytosis and modify secretory vesicle dynamics in neuroblastoma cells. J. Biol. Chem. 286 (13), 11370–11381.
Not in our library10.1074/jbc.m110.139410
163.
Hale J. S. Youngblood B. Latner D. R. Mohammed A. U. Ye L. Akondy R. S. (2013 ). Distinct memory CD4+ T cells with commitment to T follicular helper- and T helper 1-cell lineages are generated after acute viral infection. Immunity 38 (4), 805–817.
Not in our library10.1016/j.immuni.2013.02.020
164.
Han J. Liu H. Liu C. Jin H. Perlmutter J. S. Egan T. M. (2017 ). Pharmacologic characterizations of a P2X7 receptor-specific radioligand, [11C]GSK1482160 for neuroinflammatory response. Nucl. Med. Commun. 38 (5), 372–382.
Not in our library10.1097/mnm.0000000000000660
165.
Hansen M. A. Barden J. A. Balcar V. J. Keay K. A. Bennett M. R. (1997 ). Structural motif and characteristics of the extracellular domain of P2X receptors. Biochem. Biophys. Res. Commun. 236 (3), 670–675.
Not in our library10.1006/bbrc.1997.6815
166.
Harkat M. Peverini L. Cerdan A. H. Dunning K. Beudez J. Martz A. (2017 ). On the permeation of large organic cations through the pore of ATP-gated P2X receptors. Proc. Natl. Acad. Sci. U. S. A 114 (19), E3786–E3E95.
Not in our library10.1073/pnas.1701379114
167.
Hattori M. Gouaux E. (2012 ). Molecular mechanism of ATP binding and ion channel activation in P2X receptors. Nature 485 (7397), 207–212.
Not in our library10.1038/nature11010
168.
Hattori F. Ohshima Y. Seki S. Tsukimoto M. Sato M. Takenouchi T. (2012 ). Feasibility study of B16 melanoma therapy using oxidized ATP to target purinergic receptor P2X7. Eur. J. Pharmacol. 695 (1-3), 20–26.
Not in our library10.1016/j.ejphar.2012.09.001
169.
Hibell A. D. Thompson K. M. Simon J. Xing M. Humphrey P. P. Michel A. D. (2001 ). Species- and agonist-dependent differences in the deactivation-kinetics of P2X7 receptors. Naunyn Schmiedebergs Arch. Pharmacol. 363 (6), 639–648.
Not in our library10.1007/s002100100412
170.
Hickman S. E. Khoury J. Greenberg S. Schieren I. Silverstein S. C. (1994 ). P2Z adenosine triphosphate receptor activity in cultured human monocyte-derived macrophages. Blood 84 (8), 2452–2456.
Not in our library10.1182/blood.v84.8.2452.2452
171.
Honore P. Donnelly-Roberts D. Namovic M. T. Hsieh G. Zhu C. Z. Mikusa J. P. (2006 ). A-740003 [N-(1-{[(cyanoimino)(5-quinolinylamino) methyl]amino}-2,2-dimethylpropyl)-2-(3,4-dimethoxyphenyl)acetamide], a novel and selective P2X7 receptor antagonist, dose-dependently reduces neuropathic pain in the rat. J. Pharmacol. Exp. Ther. 319 (3), 1376–1385.
Not in our library10.1124/jpet.106.111559
172.
Honore P. Donnelly-Roberts D. Namovic M. Zhong C. Wade C. Chandran P. (2009 ). The antihyperalgesic activity of a selective P2X7 receptor antagonist, A-839977, is lost in IL-1alphabeta knockout mice. Behav. Brain Res. 204 (1), 77–81.
Not in our library10.1016/j.bbr.2009.05.018
173.
Hou Z. Cao J. (2016 ). Comparative study of the P2X gene family in animals and plants. Purinerg. Signal 12 (2), 269–281.
Not in our library10.1007/s11302-016-9501-z
174.
Hu J. Ye F. Cui M. Lee P. Wei C. Hao Y. (2016 ). Protein Profiling of Bladder Urothelial Cell Carcinoma. PloS One 11 (9), e0161922.
Not in our library10.1371/journal.pone.0161922
175.
Huang S. Chen Y. Wu W. Ouyang N. Chen J. Li H. (2013 ). miR-150 promotes human breast cancer growth and malignant behavior by targeting the pro-apoptotic purinergic P2X7 receptor. PloS One 8 (12), e80707.
Not in our library10.1371/journal.pone.0080707
176.
Humphreys B. D. Dubyak G. R. (1996 ). Induction of the P2z/P2X7 nucleotide receptor and associated phospholipase D activity by lipopolysaccharide and IFN-gamma in the human THP-1 monocytic cell line. J. Immunol. 157 (12), 5627–5637.
Not in our library
177.
Humphreys B. D. Rice J. Kertesy S. B. Dubyak G. R. (2000 ). Stress-activated protein kinase/JNK activation and apoptotic induction by the macrophage P2X7 nucleotide receptor. J. Biol. Chem. 275 (35), 26792–26798.
Not in our library10.1074/jbc.m002770200
178.
Huo H. Fryatt A. G. Farmer L. K. Schmid R. Evans R. J. (2018 ). Mapping the binding site of the P2X receptor antagonist PPADS reveals the importance of orthosteric site charge and the cysteine-rich head region. J. Biol. Chem. 293 (33), 12820–12831.
Not in our library10.1074/jbc.ra118.003737
179.
Idzko M. Dichmann S. Ferrari D. Di Virgilio F. la Sala A. Girolomoni G. (2002 ). Nucleotides induce chemotaxis and actin polymerization in immature but not mature human dendritic cells via activation of pertussis toxin-sensitive P2y receptors. Blood 100 (3), 925–932.
Not in our library10.1182/blood.v100.3.925
180.
Jacobson K. A. Muller C. E. (2016 ). Medicinal chemistry of adenosine, P2Y and P2X receptors. Neuropharmacology 104, 31–49.
Not in our library10.1016/j.neuropharm.2015.12.001
181.
Jacobson K. A. Jarvis M. F. Williams M. (2002 ). Purine and pyrimidine (P2) receptors as drug targets. J. Med. Chem. 45 (19), 4057–4093.
Not in our library10.1021/jm020046y
182.
Janks L. Sharma C. V. R. Egan T. M. (2018 ). A central role for P2X7 receptors in human microglia. J. Neuroinflammation 15 (1), 325.
Not in our library10.1186/s12974-018-1353-8
183.
Jarvis M. F. Khakh B. S. (2009 ). ATP-gated P2X cation-channels. Neuropharmacology 56 (1), 208–215.
Not in our library10.1016/j.neuropharm.2008.06.067
184.
Jelassi B. Chantome A. Alcaraz-Perez F. Baroja-Mazo A. Cayuela M. L. Pelegrin P. (2011 ). P2X(7) receptor activation enhances SK3 channels- and cystein cathepsin-dependent cancer cells invasiveness. Oncogene 30 (18), 2108–2122.
Not in our library10.1038/onc.2010.593
185.
Jelassi B. Anchelin M. Chamouton J. Cayuela M. L. Clarysse L. Li J. (2013 ). Anthraquinone emodin inhibits human cancer cell invasiveness by antagonizing P2X7 receptors. Carcinogenesis 34 (7), 1487–1496.
Not in our library10.1093/carcin/bgt099
186.
Ji Z. Xie Y. Guan Y. Zhang Y. Cho K. S. Ji M. (2018 ). Involvement of P2X7 Receptor in Proliferation and Migration of Human Glioma Cells. BioMed. Res. Int. 2018, 8591397.
Not in our library10.1155/2018/8591397
187.
Jiang L. H. Baldwin J. M. Roger S. Baldwin S. A. (2013 ). Insights into the Molecular Mechanisms Underlying Mammalian P2X7 Receptor Functions and Contributions in Diseases, Revealed by Structural Modeling and Single Nucleotide Polymorphisms. Front. Pharmacol. 4, 55.
Not in our library10.3389/fphar.2013.00055
188.
Jorgensen N. R. Husted L. B. Skarratt K. K. Stokes L. Tofteng C. L. Kvist T. (2012 ). Single-nucleotide polymorphisms in the P2X7 receptor gene are associated with post-menopausal bone loss and vertebral fractures. Eur. J. Hum. Genet. 20 (6), 675–681.
Not in our library10.1038/ejhg.2011.253
189.
Molecular and functional properties of P2X receptors—recent progress and persisting challenges · 2012
No notice
190.
Kaiho H. Matsuoka I. Kimura J. Nakanishi H. (1998 ). Identification of P2X7 (P2Z) receptor in N18TG-2 cells and NG108-15 cells. J. Neurochem. 70 (3), 951–957.
Not in our library10.1046/j.1471-4159.1998.70030951.x
191.
Kan L. K. Williams D. Drummond K. O’Brien T. Monif M. (2019 ). The role of microglia and P2X7 receptors in gliomas. J. Neuroimmunol. 332, 138–146.
Not in our library10.1016/j.jneuroim.2019.04.010
192.
Kang R. Zeh H. Lotze M. Tang D. (2020 ). The Multifaceted Effects of Autophagy on the Tumor Microenvironment. Adv. Exp. Med. Biol. 1225, 99–114.
Not in our library10.1007/978-3-030-35727-6_7
193.
Structural basis for subtype-specific inhibition of the P2X7 receptor · 2016
No notice
194.
The P2X7 receptor forms a dye-permeable pore independent of its intracellular domain but dependent on membrane lipid composition · 2017
No notice
195.
Kasuya G. Fujiwara Y. Tsukamoto H. Morinaga S. Ryu S. Touhara K. (2017 ). Structural insights into the nucleotide base specificity of P2X receptors. Sci. Rep. 7, 45208.
Not in our library10.1038/srep45208
196.
Kasuya G. Yamaura T. Ma X. B. Nakamura R. Takemoto M. Nagumo H. (2017 ). Structural insights into the competitive inhibition of the ATP-gated P2X receptor channel. Nat. Commun. 8 (1), 876.
Not in our library10.1038/s41467-017-00887-9
197.
Kataoka A. Tozaki-Saitoh H. Koga Y. Tsuda M. Inoue K. (2009 ). Activation of P2X7 receptors induces CCL3 production in microglial cells through transcription factor NFAT. J. Neurochem. 108 (1), 115–125.
Not in our library10.1111/j.1471-4159.2008.05744.x
198.
Kawate T. Michel J. C. Birdsong W. T. Gouaux E. (2009 ). Crystal structure of the ATP-gated P2X(4) ion channel in the closed state. Nature 460 (7255), 592–598.
Not in our library10.1038/nature08198
199.
Keystone E. C. Wang M. M. Layton M. Hollis S. McInnes I. B. Team D. C. S. (2012 ). Clinical evaluation of the efficacy of the P2X7 purinergic receptor antagonist AZD9056 on the signs and symptoms of rheumatoid arthritis in patients with active disease despite treatment with methotrexate or sulphasalazine. Ann. Rheum. Dis. 71 (10), 1630–1635.
Not in our library10.1136/annrheumdis-2011-143578
200.
Khakh B. S. Lester H. A. (1999 ). Dynamic selectivity filters in ion channels. Neuron 23 (4), 653–658.
Not in our library10.1016/s0896-6273(01)80025-8
201.
Kim M. Jiang L. H. Wilson H. L. North R. A. Surprenant A. (2001 ). Proteomic and functional evidence for a P2X7 receptor signalling complex. EMBO J. 20 (22), 6347–6358.
Not in our library10.1093/emboj/20.22.6347
202.
P2X7 Interactions and Signaling – Making Head or Tail of It · 2019
No notice
203.
Koshimizu T. Koshimizu M. Stojilkovic S. S. (1999 ). Contributions of the C-terminal domain to the control of P2X receptor desensitization. J. Biol. Chem. 274 (53), 37651–37657.
Not in our library10.1074/jbc.274.53.37651
204.
Kuehnel M. P. Rybin V. Anand P. K. Anes E. Griffiths G. (2009 ). Lipids regulate P2X7-receptor-dependent actin assembly by phagosomes via ADP translocation and ATP synthesis in the phagosome lumen. J. Cell Sci. 122 (Pt 4), 499–504.
Not in our library10.1242/jcs.034199
205.
Kunzli B. M. Berberat P. O. Giese T. Csizmadia E. Kaczmarek E. Baker C. (2007 ). Upregulation of CD39/NTPDases and P2 receptors in human pancreatic disease. Am. J. Physiol. Gastrointest. Liver Physiol. 292 (1), G223–G230.
Not in our library10.1152/ajpgi.00259.2006
206.
Kunzli B. M. Bernlochner M. I. Rath S. Kaser S. Csizmadia E. Enjyoji K. (2011 ). Impact of CD39 and purinergic signalling on the growth and metastasis of colorectal cancer. Purinerg. Signal 7 (2), 231–241.
Not in our library10.1007/s11302-011-9228-9
207.
Kurashima Y. Amiya T. Nochi T. Fujisawa K. Haraguchi T. Iba H. (2012 ). Extracellular ATP mediates mast cell-dependent intestinal inflammation through P2X7 purinoceptors. Nat. Commun. 3, 1034.
Not in our library10.1038/ncomms2023
208.
Kwon J. H. Nam E. S. Shin H. S. Cho S. J. Park H. R. Kwon M. J. (2014 ). P2X7 Receptor Expression in Coexistence of Papillary Thyroid Carcinoma with Hashimoto’s Thyroiditis. Korean J. Pathol. 48 (1), 30–35.
Not in our library10.4132/koreanjpathol.2014.48.1.30
209.
Lawrence M. S. Stojanov P. Mermel C. H. Robinson J. T. Garraway L. A. Golub T. R. (2014 ). Discovery and saturation analysis of cancer genes across 21 tumour types. Nature 505 (7484), 495–501.
Not in our library10.1038/nature12912
210.
Ledderose C. Woehrle T. Ledderose S. Strasser K. Seist R. Bao Y. (2016 ). Cutting off the power: inhibition of leukemia cell growth by pausing basal ATP release and P2X receptor signaling? Purinerg. Signal 12 (3), 439–451.
Not in our library10.1007/s11302-016-9510-y
211.
Lenertz L. Y. Gavala M. L. Hill L. M. Bertics P. J. (2009 ). Cell signaling via the P2X(7) nucleotide receptor: linkage to ROS production, gene transcription, and receptor trafficking. Purinerg. Signal 5 (2), 175–187.
Not in our library10.1007/s11302-009-9133-7
212.
Lenertz L. Y. Wang Z. Guadarrama A. Hill L. M. Gavala M. L. Bertics P. J. (2010 ). Mutation of putative N-linked glycosylation sites on the human nucleotide receptor P2X7 reveals a key residue important for receptor function. Biochemistry 49 (22), 4611–4619.
Not in our library10.1021/bi902083n
213.
Li X. Zhou L. Feng Y. H. Abdul-Karim F. W. Gorodeski G. I. (2006 ). The P2X7 receptor: a novel biomarker of uterine epithelial cancers. Cancer Epidemiol. Biomarkers Prev. 15 (10), 1906–1913.
Not in our library10.1158/1055-9965.epi-06-0407
214.
Li X. Qi X. Zhou L. Catera D. Rote N. S. Potashkin J. (2007 ). Decreased expression of P2X7 in endometrial epithelial pre-cancerous and cancer cells. Gynecol. Oncol. 106 (1), 233–243.
Not in our library10.1016/j.ygyno.2007.03.032
215.
Li X. Qi X. Zhou L. Fu W. Abdul-Karim F. W. Maclennan G. (2009 ). P2X(7) receptor expression is decreased in epithelial cancer cells of ectodermal, uro-genital sinus, and distal paramesonephric duct origin. Purinerg. Signal 5 (3), 351–368.
Not in our library10.1007/s11302-009-9161-3
216.
Li M. Toombes G. E. Silberberg S. D. Swartz K. J. (2015 ). Physical basis of apparent pore dilation of ATP-activated P2X receptor channels. Nat. Neurosci. 18 (11), 1577–1583.
Not in our library10.1038/nn.4120
217.
Li X. Y. Moesta A. K. Xiao C. Nakamura K. Casey M. Zhang H. (2019 ). Targeting CD39 in Cancer Reveals an Extracellular ATP- and Inflammasome-Driven Tumor Immunity. Cancer Discovery 9 (12), 1754–1773.
Not in our library10.1158/2159-8290.cd-19-0541
218.
Liang X. Samways D. S. K. Cox J. Egan T. M. (2019 ). Ca(2+) flux through splice variants of the ATP-gated ionotropic receptor P2X7 is regulated by its cytoplasmic N terminus. J. Biol. Chem. 294 (33), 12521–12533.
Not in our library10.1074/jbc.ra119.009666
219.
Liu P. S. Chen C. Y. (2010 ). Butyl benzyl phthalate suppresses the ATP-induced cell proliferation in human osteosarcoma HOS cells. Toxicol. Appl. Pharmacol. 244 (3), 308–314.
Not in our library10.1016/j.taap.2010.01.007
220.
Liu Y. Xiao Y. Li Z. (2011 ). P2X7 receptor positively regulates MyD88-dependent NF-kappaB activation. Cytokine 55 (2), 229–236.
Not in our library10.1016/j.cyto.2011.05.003
221.
Liu Z. Liu Y. Xu L. An H. Chang Y. Yang Y. (2015 ). P2X7 receptor predicts postoperative cancer-specific survival of patients with clear-cell renal cell carcinoma. Cancer Sci. 106 (9), 1224–1231.
Not in our library10.1111/cas.12736
222.
Understanding the mechanism of IL-1β secretion · 2011
No notice
223.
Lord B. Aluisio L. Shoblock J. R. Neff R. A. Varlinskaya E. I. Ceusters M. (2014 ). Pharmacology of a novel central nervous system-penetrant P2X7 antagonist JNJ-42253432. J. Pharmacol. Exp. Ther. 351 (3), 628–641.
Not in our library10.1124/jpet.114.218487
224.
Lord B. Ameriks M. K. Wang Q. Fourgeaud L. Vliegen M. Verluyten W. (2015 ). A novel radioligand for the ATP-gated ion channel P2X7: [3H] JNJ-54232334. Eur. J. Pharmacol. 765, 551–559.
Not in our library10.1016/j.ejphar.2015.09.026
225.
Ma Y. Adjemian S. Yang H. Catani J. P. Hannani D. Martins I. (2013 ). ATP-dependent recruitment, survival and differentiation of dendritic cell precursors in the tumor bed after anticancer chemotherapy. Oncoimmunology 2 (6), e24568.
Not in our library10.4161/onci.24568
226.
MacKenzie A. Wilson H. L. Kiss-Toth E. Dower S. K. North R. A. Surprenant A. (2001 ). Rapid secretion of interleukin-1beta by microvesicle shedding. Immunity 15 (5), 825–835.
Not in our library10.1016/s1074-7613(01)00229-1
227.
Mackenzie A. B. Young M. T. Adinolfi E. Surprenant A. (2005 ). Pseudoapoptosis induced by brief activation of ATP-gated P2X7 receptors. J. Biol. Chem. 280 (40), 33968–33976.
Not in our library10.1074/jbc.m502705200
228.
Maianski Z. Pedersen J. Chabert C. Barden J. S P. D. (2007 ). 1435: Evaluation of a New Monoclonal Antibody Targeting the Apoptotic Purinergic Receptor P2x7, as a Diagnostic Tool for Prostate Cancer. J. Urol. 177 (4S), 474.
Not in our library10.1016/s0022-5347(18)31636-7
229.
Mansoor S. E. Lu W. Oosterheert W. Shekhar M. Tajkhorshid E. Gouaux E. (2016 ). X-ray structures define human P2X(3) receptor gating cycle and antagonist action. Nature 538 (7623), 66–71.
Not in our library10.1038/nature19367
230.
Martel-Gallegos G. Casas-Pruneda G. Ortega-Ortega F. Sanchez-Armass S. Olivares-Reyes J. A. Diebold B. (2013 ). Oxidative stress induced by P2X7 receptor stimulation in murine macrophages is mediated by c-Src/Pyk2 and ERK1/2. Biochim. Biophys. Acta 1830 (10), 4650–4659.
Not in our library10.1016/j.bbagen.2013.05.023
231.
Mawatwal S. Behura A. Ghosh A. Kidwai S. Mishra A. Deep A. (2017 ). Calcimycin mediates mycobacterial killing by inducing intracellular calcium-regulated autophagy in a P2RX7 dependent manner. Biochim. Biophys. Acta Gen. Subj. 1861 (12), 3190–3200.
Not in our library10.1016/j.bbagen.2017.09.010
232.
McCarthy A. E. Yoshioka C. Mansoor S. E. (2019 ). Full-Length P2X7 Structures Reveal How Palmitoylation Prevents Channel Desensitization. Cell. 179 (3), 659–670.e13.
Not in our library10.1016/j.cell.2019.09.017
233.
McInnes I. B. Cruwys S. Bowers K. Braddock M. (2014 ). Targeting the P2X7 receptor in rheumatoid arthritis: biological rationale for P2X7 antagonism. Clin. Exp. Rheumatol. 32 (6), 878–882.
Not in our library
234.
McLarnon J. G. (2017 ). Roles of purinergic P2X7 receptor in glioma and microglia in brain tumors. Cancer Lett. 402, 93–99.
Not in our library10.1016/j.canlet.2017.05.004
235.
Mehta N. Kaur M. Singh M. Chand S. Vyas B. Silakari P. (2014 ). Purinergic receptor P2X(7): a novel target for anti-inflammatory therapy. Bioorg. Med. Chem. 22 (1), 54–88.
Not in our library10.1016/j.bmc.2013.10.054
236.
Michaud M. Martins I. Sukkurwala A. Q. Adjemian S. Ma Y. Pellegatti P. (2011 ). Autophagy-dependent anticancer immune responses induced by chemotherapeutic agents in mice. Science 334 (6062), 1573–1577.
Not in our library10.1126/science.1208347
237.
Michel A. D. Fonfria E. (2007 ). Agonist potency at P2X7 receptors is modulated by structurally diverse lipids. Br. J. Pharmacol. 152 (4), 523–537.
Not in our library10.1038/sj.bjp.0707417
238.
Michel A. D. Kaur R. Chessell I. P. Humphrey P. P. (2000 ). Antagonist effects on human P2X(7) receptor-mediated cellular accumulation of YO-PRO-1. Br. J. Pharmacol. 130 (3), 513–520.
Not in our library10.1038/sj.bjp.0703368
239.
Michel A. D. Chambers L. J. Walter D. S. (2008 a). Negative and positive allosteric modulators of the P2X(7) receptor. Br. J. Pharmacol. 153 (4), 737–750.
Not in our library10.1038/sj.bjp.0707625
240.
Michel A. D. Clay W. C. Ng S. W. Roman S. Thompson K. Condreay J. P. (2008 b). Identification of regions of the P2X(7) receptor that contribute to human and rat species differences in antagonist effects. Br. J. Pharmacol. 155 (5), 738–751.
Not in our library10.1038/bjp.2008.306
241.
Michelsen K. Yuan H. Schwappach B. (2005 ). Hide and run. Arginine-based endoplasmic-reticulum-sorting motifs in the assembly of heteromultimeric membrane proteins. EMBO Rep. 6 (8), 717–722.
Not in our library10.1038/sj.embor.7400480
242.
Middaugh C. R. Mach H. Burke C. J. Volkin D. B. Dabora J. M. Tsai P. K. (1992 ). Nature of the interaction of growth factors with suramin. Biochemistry 31 (37), 9016–9024.
Not in our library10.1021/bi00152a044
243.
Minkiewicz J. de Rivero Vaccari J. P. Keane R. W. (2013 ). Human astrocytes express a novel NLRP2 inflammasome. Glia 61 (7), 1113–1121.
Not in our library10.1002/glia.22499
244.
Mistafa O. Stenius U. (2009 ). Statins inhibit Akt/PKB signaling via P2X7 receptor in pancreatic cancer cells. Biochem. Pharmacol. 78 (9), 1115–1126.
Not in our library10.1016/j.bcp.2009.06.016
245.
Moncao-Ribeiro L. C. Faffe D. S. Santana P. T. Vieira F. S. da Graca C. L. Marques-da-Silva C. (2014 ). P2X7 receptor modulates inflammatory and functional pulmonary changes induced by silica. PloS One 9 (10), e110185.
Not in our library10.1371/journal.pone.0110185
246.
Monif M. Reid C. A. Powell K. L. Smart M. L. Williams D. A. (2009 ). The P2X7 receptor drives microglial activation and proliferation: a trophic role for P2X7R pore. J. Neurosci. 29 (12), 3781–3791.
Not in our library10.1523/jneurosci.5512-08.2009
247.
Moore S. F. MacKenzie A. B. (2007 ). Murine macrophage P2X7 receptors support rapid prothrombotic responses. Cell Signal 19 (4), 855–866.
Not in our library10.1016/j.cellsig.2006.10.010
248.
Moore S. F. MacKenzie A. B. (2009 ). NADPH oxidase NOX2 mediates rapid cellular oxidation following ATP stimulation of endotoxin-primed macrophages. J. Immunol. 183 (5), 3302–3308.
Not in our library10.4049/jimmunol.0900394
249.
Morciano G. Sarti A. C. Marchi S. Missiroli S. Falzoni S. Raffaghello L. (2017 ). Use of luciferase probes to measure ATP in living cells and animals. Nat. Protoc. 12 (8), 1542–1562.
Not in our library10.1038/nprot.2017.052
250.
Morelli A. Chiozzi P. Chiesa A. Ferrari D. Sanz J. M. Falzoni S. (2003 ). Extracellular ATP causes ROCK I-dependent bleb formation in P2X7-transfected HEK293 cells. Mol. Biol. Cell 14 (7), 2655–2664.
Not in our library10.1091/mbc.02-04-0061
251.
Mulcahy Levy J. M. Thorburn A. (2020 ). Autophagy in cancer: moving from understanding mechanism to improving therapy responses in patients. Cell Death Differ. 27 (3), 843–857.
Not in our library10.1038/s41418-019-0474-7
252.
Munoz-Planillo R. Kuffa P. Martinez-Colon G. Smith B. L. Rajendiran T. M. Nunez G. (2013 ). K(+) efflux is the common trigger of NLRP3 inflammasome activation by bacterial toxins and particulate matter. Immunity 38 (6), 1142–1153.
Not in our library10.1016/j.immuni.2013.05.016
253.
Mutini C. Falzoni S. Ferrari D. Chiozzi P. Morelli A. Baricordi O. R. (1999 ). Mouse dendritic cells express the P2X7 purinergic receptor: characterization and possible participation in antigen presentation. J. Immunol. 163 (4), 1958–1965.
Not in our library
254.
Nelson D. W. Gregg R. J. Kort M. E. Perez-Medrano A. Voight E. A. Wang Y. (2006 ). Structure-activity relationship studies on a series of novel, substituted 1-benzyl-5-phenyltetrazole P2X7 antagonists. J. Med. Chem. 49 (12), 3659–3666.
Not in our library10.1021/jm051202e
255.
Noguchi T. Ishii K. Fukutomi H. Naguro I. Matsuzawa A. Takeda K. (2008 ). Requirement of reactive oxygen species-dependent activation of ASK1-p38 MAPK pathway for extracellular ATP-induced apoptosis in macrophage. J. Biol. Chem. 283 (12), 7657–7665.
Not in our library10.1074/jbc.m708402200
256.
North R. A. Surprenant A. (2000 ). Pharmacology of cloned P2X receptors. Annu. Rev. Pharmacol. Toxicol. 40, 563–580.
Not in our library10.1146/annurev.pharmtox.40.1.563
257.
North R. A. (2002 ). Molecular physiology of P2X receptors. Physiol. Rev. 82 (4), 1013–1067.
Not in our library10.1152/physrev.00015.2002
258.
Orioli E. De Marchi E. Giuliani A. L. Adinolfi E. (2017 ). P2X7 receptor orchestrates multiple signalling pathways triggering inflammation, autophagy and metabolic/trophic responses. Curr. Med. Chem. 24 (21), 2261–2275.
Not in our library10.2174/0929867324666170303161659
259.
Overes I. M. de Rijke B. van Horssen-Zoetbrood A. Fredrix H. de Graaf A. O. Jansen J. H. (2008 ). Expression of P2X5 in lymphoid malignancies results in LRH-1-specific cytotoxic T-cell-mediated lysis. Br. J. Haematol. 141 (6), 799–807.
Not in our library10.1111/j.1365-2141.2008.07125.x
260.
Oyanguren-Desez O. Rodriguez-Antiguedad A. Villoslada P. Domercq M. Alberdi E. Matute C. (2011 ). Gain-of-function of P2X7 receptor gene variants in multiple sclerosis. Cell Calcium 50 (5), 468–472.
Not in our library10.1016/j.ceca.2011.08.002
261.
Pandolfi J. B. Ferraro A. A. Sananez I. Gancedo M. C. Baz P. Billordo L. A. (2016 ). ATP-Induced Inflammation Drives Tissue-Resident Th17 Cells in Metabolically Unhealthy Obesity. J. Immunol. 196 (8), 3287–3296.
Not in our library10.4049/jimmunol.1502506
262.
Panenka W. Jijon H. Herx L. M. Armstrong J. N. Feighan D. Wei T. (2001 ). P2X7-like receptor activation in astrocytes increases chemokine monocyte chemoattractant protein-1 expression via mitogen-activated protein kinase. J. Neurosci. 21 (18), 7135–7142.
Not in our library10.1523/jneurosci.21-18-07135.2001
263.
Panupinthu N. Rogers J. T. Zhao L. Solano-Flores L. P. Possmayer F. Sims S. M. (2008 ). P2X7 receptors on osteoblasts couple to production of lysophosphatidic acid: a signaling axis promoting osteogenesis. J. Cell Biol. 181 (5), 859–871.
Not in our library10.1083/jcb.200708037
264.
Park J. H. Kim Y. C. (2017 ). P2X7 receptor antagonists: a patent review (2010-2015). Expert Opin. Ther. Pat. 27 (3), 257–267.
Not in our library10.1080/13543776.2017.1246538
265.
Park J. H. Williams D. R. Lee J. H. Lee S. D. Lee J. H. Ko H. (2016 ). Potent Suppressive Effects of 1-Piperidinylimidazole Based Novel P2X7 Receptor Antagonists on Cancer Cell Migration and Invasion. J. Med. Chem. 59 (16), 7410–7430.
Not in our library10.1021/acs.jmedchem.5b01690
266.
Park M. Kim J. Phuong N. T. T. Park J. G. Park J. H. Kim Y. C. (2019 ). Involvement of the P2X7 receptor in the migration and metastasis of tamoxifen-resistant breast cancer: effects on small extracellular vesicles production. Sci. Rep. 9 (1), 11587.
Not in our library10.1038/s41598-019-47734-z
267.
Parvathenani L. K. Tertyshnikova S. Greco C. R. Roberts S. B. Robertson B. Posmantur R. (2003 ). P2X7 mediates superoxide production in primary microglia and is up-regulated in a transgenic mouse model of Alzheimer’s disease. J. Biol. Chem. 278 (15), 13309–13317.
Not in our library10.1074/jbc.m209478200
268.
Patel C. H. Powell J. D. (2017 ). Targeting T cell metabolism to regulate T cell activation, differentiation and function in disease. Curr. Opin. Immunol. 46, 82–88.
Not in our library10.1016/j.coi.2017.04.006
269.
Pegoraro A. Bortolotti D. Marci R. Caselli E. Falzoni S. De Marchi E. (2020 ). The P2X7 Receptor 489C>T Gain of Function Polymorphism Favors HHV-6A Infection and Associates With Female Idiopathic Infertility. Front. Pharmacol. 11 (96).
Not in our library10.3389/fphar.2020.00096
270.
Pelegrin P. Barroso-Gutierrez C. Surprenant A. (2008 ). P2X7 receptor differentially couples to distinct release pathways for IL-1beta in mouse macrophage. J. Immunol. 180 (11), 7147–7157.
Not in our library10.4049/jimmunol.180.11.7147
271.
Pellegatti P. Falzoni S. Pinton P. Rizzuto R. Di Virgilio F. (2005 ). A novel recombinant plasma membrane-targeted luciferase reveals a new pathway for ATP secretion. Mol. Biol. Cell 16 (8), 3659–3665.
Not in our library10.1091/mbc.e05-03-0222
272.
Increased Level of Extracellular ATP at Tumor Sites: In Vivo Imaging with Plasma Membrane Luciferase · 2008
No notice
273.
Peng L. Bradley C. J. Wiley J. S. (1999 ). P2Z purinoceptor, a special receptor for apoptosis induced by ATP in human leukemic lymphocytes. Chin. Med. J. (Engl.) 112 (4), 356–362.
Not in our library
274.
Perregaux D. G. Gabel C. A. (1998 ). Human monocyte stimulus-coupled IL-1beta posttranslational processing: modulation via monovalent cations. Am. J. Physiol. 275 (6), C1538–C1547.
Not in our library10.1152/ajpcell.1998.275.6.c1538
275.
Perregaux D. G. McNiff P. Laliberte R. Conklyn M. Gabel C. A. (2000 ). ATP acts as an agonist to promote stimulus-induced secretion of IL-1 beta and IL-18 in human blood. J. Immunol. 165 (8), 4615–4623.
Not in our library10.4049/jimmunol.165.8.4615
276.
Perruzza L. Gargari G. Proietti M. Fosso B. D’Erchia A. M. Faliti C. E. (2017 ). T Follicular Helper Cells Promote a Beneficial Gut Ecosystem for Host Metabolic Homeostasis by Sensing Microbiota-Derived Extracellular ATP. Cell Rep. 18 (11), 2566–2575.
Not in our library10.1016/j.celrep.2017.02.061
277.
Pevarello P. Bovolenta S. Tarroni P. Za L. Severi E. Torino D. (2017 ). P2X7 antagonists for CNS indications: recent patent disclosures. Pharm. Pat. Anal. 6 (2), 61–76.
Not in our library10.4155/ppa-2016-0044
278.
Piccioli P. Rubartelli A. (2013 ). The secretion of IL-1beta and options for release. Semin. Immunol. 25 (6), 425–429.
Not in our library10.1016/j.smim.2013.10.007
279.
Pietrocola F. Pol J. Vacchelli E. Rao S. Enot D. P. Baracco E. E. (2016 ). Caloric Restriction Mimetics Enhance Anticancer Immunosurveillance. Cancer Cell 30 (1), 147–160.
Not in our library10.1016/j.ccell.2016.05.016
280.
Pippel A. Stolz M. Woltersdorf R. Kless A. Schmalzing G. Markwardt F. (2017 ). Localization of the gate and selectivity filter of the full-length P2X7 receptor. Proc. Natl. Acad. Sci. U. S. A 114 (11), E2156–E2E65.
Not in our library10.1073/pnas.1610414114
281.
Pizzirani C. Ferrari D. Chiozzi P. Adinolfi E. Sandona D. Savaglio E. (2007 ). Stimulation of P2 receptors causes release of IL-1beta-loaded microvesicles from human dendritic cells. Blood 109 (9), 3856–3864.
Not in our library10.1182/blood-2005-06-031377
282.
Proietti M. Perruzza L. Scribano D. Pellegrini G. D’Antuono R. Strati F. (2019 ). ATP released by intestinal bacteria limits the generation of protective IgA against enteropathogens. Nat. Commun. 10 (1), 250.
Not in our library10.1038/s41467-018-08156-z
283.
Qian F. Xiao J. Hu B. Sun N. Yin W. Zhu J. (2017 ). High expression of P2X7R is an independent postoperative indicator of poor prognosis in colorectal cancer. Hum. Pathol. 64, 61–68.
Not in our library10.1016/j.humpath.2017.03.019
284.
Qiu Y. Li W. H. Zhang H. Q. Liu Y. Tian X. X. Fang W. G. (2014 ). P2X7 mediates ATP-driven invasiveness in prostate cancer cells. PloS One 9 (12), e114371.
Not in our library10.1371/journal.pone.0114371
285.
Qu Y. Dubyak G. R. (2009 ). P2X7 receptors regulate multiple types of membrane trafficking responses and non-classical secretion pathways. Purinerg. Signal 5 (2), 163–173.
Not in our library10.1007/s11302-009-9132-8
286.
Qu Y. Franchi L. Nunez G. Dubyak G. R. (2007 ). Nonclassical IL-1 beta secretion stimulated by P2X7 receptors is dependent on inflammasome activation and correlated with exosome release in murine macrophages. J. Immunol. 179 (3), 1913–1925.
Not in our library10.4049/jimmunol.179.3.1913
287.
Raffaghello L. Chiozzi P. Falzoni S. Di Virgilio F. Pistoia V. (2006 ). The P2X7 receptor sustains the growth of human neuroblastoma cells through a substance P-dependent mechanism. Cancer Res. 66 (2), 907–914.
Not in our library10.1158/0008-5472.can-05-3185
288.
Ravenna L. Sale P. Di Vito M. Russo A. Salvatori L. Tafani M. (2009 ). Up-regulation of the inflammatory-reparative phenotype in human prostate carcinoma. Prostate 69 (11), 1245–1255.
Not in our library10.1002/pros.20966
289.
Reczek C. R. Chandel N. S. (2015 ). ROS-dependent signal transduction. Curr. Opin. Cell Biol. 33, 8–13.
Not in our library10.1016/j.ceb.2014.09.010
290.
Reinhold W. C. Sunshine M. Liu H. Varma S. Kohn K. W. Morris J. (2012 ). CellMiner: a web-based suite of genomic and pharmacologic tools to explore transcript and drug patterns in the NCI-60 cell line set. Cancer Res. 72 (14), 3499–3511.
Not in our library10.1158/0008-5472.can-12-1370
291.
Rizzo R. Ferrari D. Melchiorri L. Stignani M. Gulinelli S. Baricordi O. R. (2009 ). Extracellular ATP acting at the P2X7 receptor inhibits secretion of soluble HLA-G from human monocytes. J. Immunol. 183 (7), 4302–4311.
Not in our library10.4049/jimmunol.0804265
292.
Robert R. Carlile G. W. Pavel C. Liu N. Anjos S. M. Liao J. (2008 ). Structural analog of sildenafil identified as a novel corrector of the F508del-CFTR trafficking defect. Mol. Pharmacol. 73 (2), 478–489.
Not in our library10.1124/mol.107.040725
293.
Robinson L. E. Murrell-Lagnado R. D. (2013 ). The trafficking and targeting of P2X receptors. Front. Cell Neurosci. 7, 233.
Not in our library10.3389/fncel.2013.00233
294.
Robinson L. E. Shridar M. Smith P. Murrell-Lagnado R. D. (2014 ). Plasma membrane cholesterol as a regulator of human and rodent P2X7 receptor activation and sensitization. J. Biol. Chem. 289 (46), 31983–31994.
Not in our library10.1074/jbc.m114.574699
295.
Roger S. Mei Z. Z. Baldwin J. M. Dong L. Bradley H. Baldwin S. A. (2010 ). Single nucleotide polymorphisms that were identified in affective mood disorders affect ATP-activated P2X7 receptor functions. J. Psychiatr. Res. 44 (6), 347–355.
Not in our library10.1016/j.jpsychires.2009.10.005
296.
Roger S. Jelassi B. Couillin I. Pelegrin P. Besson P. Jiang L. H. (2015 ). Understanding the roles of the P2X7 receptor in solid tumour progression and therapeutic perspectives. Biochim. Biophys. Acta 1848 (10 Pt B), 2584–2602.
Not in our library10.1016/j.bbamem.2014.10.029
297.
Rozengurt E. Heppel L. A. (1975 ). A Specific effect of external ATP on the permeability of transformed 3T3 cells. Biochem. Biophys. Res. Commun. 67 (4), 1581–1588.
Not in our library10.1016/0006-291x(75)90207-7
298.
Ruggeri R. M. Villari D. Simone A. Scarfi R. Attard M. Orlandi F. (2002 ). Co-expression of interleukin-6 (IL-6) and interleukin-6 receptor (IL-6R) in thyroid nodules is associated with co-expression of CD30 ligand/CD30 receptor. J. Endocrinol. Invest. 25 (11), 959–966.
Not in our library10.1007/bf03344068
299.
Rump A. Smolander O. P. Ruutel Boudinot S. Kanellopoulos J. M. Boudinot P. (2020 ). Evolutionary Origin of the P2X7 C-ter Region: Capture of an Ancient Ballast Domain by a P2X4-Like Gene in Ancient Jawed Vertebrates. Front. Immunol. 11, 113.
Not in our library10.3389/fimmu.2020.00113
300.
Ryu J. K. Jantaratnotai N. Serrano-Perez M. C. McGeer P. L. McLarnon J. G. (2011 ). Block of purinergic P2X7R inhibits tumor growth in a C6 glioma brain tumor animal model. J. Neuropathol. Exp. Neurol. 70 (1), 13–22.
Not in our library10.1097/nen.0b013e318201d4d4
301.
Salaro E. Rambaldi A. Falzoni S. Amoroso F. S. Franceschini A. Sarti A. C. (2016 ). Involvement of the P2X7-NLRP3 axis in leukemic cell proliferation and death. Sci. Rep. 6, 26280.
Not in our library10.1038/srep26280
302.
Salvestrini V. Orecchioni S. Talarico G. Reggiani F. Mazzetti C. Bertolini F. (2017 ). Extracellular ATP induces apoptosis through P2X7R activation in acute myeloid leukemia cells but not in normal hematopoietic stem cells. Oncotarget 8 (4), 5895–5908.
Not in our library10.18632/oncotarget.13927
303.
Santos A. A. Jr. Cappellari A. R. de Marchi F. O. Gehring M. P. Zaparte A. Brandao C. A. (2017 ). Potential role of P2X7R in esophageal squamous cell carcinoma proliferation. Purinerg. Signal 13 (3), 279–292.
Not in our library10.1007/s11302-017-9559-2
304.
Sanz J. M. Di Virgilio F. (2000 ). Kinetics and mechanism of ATP-dependent IL-1 beta release from microglial cells. J. Immunol. 164 (9), 4893–488.
Not in our library10.4049/jimmunol.164.9.4893
305.
Savio L. E. B. de Andrade Mello P. Figliuolo V. R. de Avelar Almeida T. F. Santana P. T. Oliveira S. D. S. (2017 ). CD39 limits P2X7 receptor inflammatory signaling and attenuates sepsis-induced liver injury. J. Hepatol. 67 (4), 716–726.
Not in our library10.1016/j.jhep.2017.05.021
306.
Schenk U. Westendorf A. M. Radaelli E. Casati A. Ferro M. Fumagalli M. (2008 ). Purinergic control of T cell activation by ATP released through pannexin-1 hemichannels. Sci. Signal 1 (39), ra6.
Not in our library10.1126/scisignal.1160583
307.
Schenk U. Frascoli M. Proietti M. Geffers R. Traggiai E. Buer J. (2011 ). ATP inhibits the generation and function of regulatory T cells through the activation of purinergic P2X receptors. Sci. Signal 4 (162), ra12.
Not in our library10.1126/scisignal.2001270
308.
Schmid S. Kubler M. Korcan Ayata C. Lazar Z. Haager B. Hossfeld M. (2015 ). Altered purinergic signaling in the tumor associated immunologic microenvironment in metastasized non-small-cell lung cancer. Lung Cancer 90 (3), 516–521.
Not in our library10.1016/j.lungcan.2015.10.005
309.
Schrier S. M. Florea B. I. Mulder G. J. Nagelkerke J. F. AP I. J. (2002 ). Apoptosis induced by extracellular ATP in the mouse neuroblastoma cell line N1E-115: studies on involvement of P2 receptors and adenosine. Biochem. Pharmacol. 63 (6), 1119–1126.
Not in our library10.1016/s0006-2952(01)00939-x
310.
Schwarz N. Drouot L. Nicke A. Fliegert R. Boyer O. Guse A. H. (2012 ). Alternative splicing of the N-terminal cytosolic and transmembrane domains of P2X7 controls gating of the ion channel by ADP-ribosylation. PloS One 7 (7), e41269.
Not in our library10.1371/journal.pone.0041269
311.
CellMiner: a relational database and query tool for the NCI-60 cancer cell lines · 2009
No notice
312.
Shemon A. N. Sluyter R. Fernando S. L. Clarke A. L. Dao-Ung L. P. Skarratt K. K. (2006 ). A Thr357 to Ser polymorphism in homozygous and compound heterozygous subjects causes absent or reduced P2X7 function and impairs ATP-induced mycobacterial killing by macrophages. J. Biol. Chem. 281 (4), 2079–2086.
Not in our library10.1074/jbc.m507816200
313.
Shieh C. H. Heinrich A. Serchov T. van Calker D. Biber K. (2014 ). P2X7-dependent, but differentially regulated release of IL-6, CCL2, and TNF-alpha in cultured mouse microglia. Glia 62 (4), 592–607.
Not in our library10.1002/glia.22628
314.
Shiratori M. Tozaki-Saitoh H. Yoshitake M. Tsuda M. Inoue K. (2010 ). P2X7 receptor activation induces CXCL2 production in microglia through NFAT and PKC/MAPK pathways. J. Neurochem. 114 (3), 810–819.
Not in our library10.1111/j.1471-4159.2010.06809.x
315.
Silverman W. R. de Rivero Vaccari J. P. Locovei S. Qiu F. Carlsson S. K. Scemes E. (2009 ). The pannexin 1 channel activates the inflammasome in neurons and astrocytes. J. Biol. Chem. 284 (27), 18143–18151.
Not in our library10.1074/jbc.m109.004804
316.
Sinadinos A. Young C. N. Al-Khalidi R. Teti A. Kalinski P. Mohamad S. (2015 ). P2RX7 purinoceptor: a therapeutic target for ameliorating the symptoms of duchenne muscular dystrophy. PloS Med. 12 (10), e1001888.
Not in our library10.1371/journal.pmed.1001888
317.
Slater M. Barden J. A. (2005 ). Differentiating keratoacanthoma from squamous cell carcinoma by the use of apoptotic and cell adhesion markers. Histopathology 47 (2), 170–178.
Not in our library10.1111/j.1365-2559.2005.02155.x
318.
Slater M. Scolyer R. A. Gidley-Baird A. Thompson J. F. Barden J. A. (2003 ). Increased expression of apoptotic markers in melanoma. Melanoma Res. 13 (2), 137–145.
Not in our library10.1097/01.cmr.0000056225.78713.42
319.
Slater M. Danieletto S. Gidley-Baird A. Teh L. C. Barden J. A. (2004 a). Early prostate cancer detected using expression of non-functional cytolytic P2X7 receptors. Histopathology 44 (3), 206–15.
Not in our library10.1111/j.0309-0167.2004.01798.x
320.
Slater M. Danieletto S. Pooley M. Cheng Teh L. Gidley-Baird A. Barden J. A. (2004 b). Differentiation between cancerous and normal hyperplastic lobules in breast lesions. Breast Cancer Res. Treat 83 (1), 1–10.
Not in our library10.1023/b:brea.0000010670.85915.0f
321.
Slater M. Danieletto S. Barden J. A. (2005 ). Expression of the apoptotic calcium channel P2X7 in the glandular epithelium. J. Mol. Histol. 36 (3), 159–165.
Not in our library10.1007/s10735-004-6166-7
322.
Sluyter R. Stokes L. (2011 ). Significance of P2X7 receptor variants to human health and disease. Recent Pat. DNA Gene Seq. 5 (1), 41–54.
Not in our library10.2174/187221511794839219
323.
Smart M. L. Gu B. Panchal R. G. Wiley J. Cromer B. Williams D. A. (2003 ). P2X7 receptor cell surface expression and cytolytic pore formation are regulated by a distal C-terminal region. J. Biol. Chem. 278 (10), 8853–8860.
Not in our library10.1074/jbc.m211094200
324.
Solini A. Chiozzi P. Morelli A. Fellin R. Di Virgilio F. (1999 ). Human primary fibroblasts in vitro express a purinergic P2X7 receptor coupled to ion fluxes, microvesicle formation and IL-6 release. J. Cell Sci. 112 (Pt 3), 297–305.
Not in our library10.1242/jcs.112.3.297
325.
Solini A. Cuccato S. Ferrari D. Santini E. Gulinelli S. Callegari M. G. (2008 ). Increased P2X7 receptor expression and function in thyroid papillary cancer: a new potential marker of the disease? Endocrinology 149 (1), 389–396.
Not in our library10.1210/en.2007-1223
326.
Solini A. Simeon V. Derosa L. Orlandi P. Rossi C. Fontana A. (2015 ). Genetic interaction of P2X7 receptor and VEGFR-2 polymorphisms identifies a favorable prognostic profile in prostate cancer patients. Oncotarget 6 (30), 28743–28754.
Not in our library10.18632/oncotarget.4926
327.
Solle M. Labasi J. Perregaux D. G. Stam E. Petrushova N. Koller B. H. (2001 ). Altered cytokine production in mice lacking P2X(7) receptors. J. Biol. Chem. 276 (1), 125–132.
Not in our library10.1074/jbc.m006781200
328.
Sorge R. E. Trang T. Dorfman R. Smith S. B. Beggs S. Ritchie J. (2012 ). Genetically determined P2X7 receptor pore formation regulates variability in chronic pain sensitivity. Nat. Med. 18 (4), 595–599.
Not in our library10.1038/nm.2710
329.
Steinberg T. H. Newman A. S. Swanson J. A. Silverstein S. C. (1987 ). ATP4- permeabilizes the plasma membrane of mouse macrophages to fluorescent dyes. J. Biol. Chem. 262 (18), 8884–8888.
Not in our library
330.
Stock T. C. Bloom B. J. Wei N. Ishaq S. Park W. Wang X. (2012 ). Efficacy and safety of CE-224,535, an antagonist of P2X7 receptor, in treatment of patients with rheumatoid arthritis inadequately controlled by methotrexate. J. Rheumatol. 39 (4), 720–727.
Not in our library10.3899/jrheum.110874
331.
Stokes L. Jiang L. H. Alcaraz L. Bent J. Bowers K. Fagura M. (2006 ). Characterization of a selective and potent antagonist of human P2X(7) receptors, AZ11645373. Br. J. Pharmacol. 149 (7), 880–887.
Not in our library10.1038/sj.bjp.0706933
332.
Stokes L. Fuller S. J. Sluyter R. Skarratt K. K. Gu B. J. Wiley J. S. (2010 ). Two haplotypes of the P2X(7) receptor containing the Ala-348 to Thr polymorphism exhibit a gain-of-function effect and enhanced interleukin-1beta secretion. FASEB J. 24 (8), 2916–2927.
Not in our library10.1096/fj.09-150862
333.
Sun C. Chu J. Singh S. Salter R. D. (2010 ). Identification and characterization of a novel variant of the human P2X(7) receptor resulting in gain of function. Purinerg. Signal 6 (1), 31–45.
Not in our library10.1007/s11302-009-9168-9
334.
Sun L. Gao J. Zhao M. Cui J. Li Y. Yang X. (2015 ). A novel cognitive impairment mechanism that astrocytic p-connexin 43 promotes neuronic autophagy via activation of P2X7R and down-regulation of GLT-1 expression in the hippocampus following traumatic brain injury in rats. Behav. Brain Res. 291, 315–324.
Not in our library10.1016/j.bbr.2015.05.049
335.
Sun S. H. (2010 ). Roles of P2X7 receptor in glial and neuroblastoma cells: the therapeutic potential of P2X7 receptor antagonists. Mol. Neurobiol. 41 (2-3), 351–355.
Not in our library10.1007/s12035-010-8120-x
336.
Surprenant A. Rassendren F. Kawashima E. North R. A. Buell G. (1996 ). The cytolytic P2Z receptor for extracellular ATP identified as a P2X receptor (P2X7). Science 272 (5262), 735–738.
Not in our library10.1126/science.272.5262.735
337.
Swanson D. M. Savall B. M. Coe K. J. Schoetens F. Koudriakova T. Skaptason J. (2016 ). Identification of (R)-(2-Chloro-3-(trifluoromethyl)phenyl)(1-(5-fluoropyridin-2-yl)-4-methyl-6,7-di hydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone (JNJ 54166060), a Small Molecule Antagonist of the P2X7 receptor. J. Med. Chem. 59 (18), 8535–8548.
Not in our library10.1021/acs.jmedchem.6b00989
338.
Tafani M. Russo A. Di Vito M. Sale P. Pellegrini L. Schito L. (2010 ). Up-regulation of pro-inflammatory genes as adaptation to hypoxia in MCF-7 cells and in human mammary invasive carcinoma microenvironment. Cancer Sci. 101 (4), 1014–1023.
Not in our library10.1111/j.1349-7006.2010.01493.x
339.
Tafani M. Di Vito M. Frati A. Pellegrini L. De Santis E. Sette G. (2011 ). Pro-inflammatory gene expression in solid glioblastoma microenvironment and in hypoxic stem cells from human glioblastoma. J. Neuroinflammation 8, 32.
Not in our library10.1186/1742-2094-8-32
340.
Takai E. Tsukimoto M. Harada H. Sawada K. Moriyama Y. Kojima S. (2012 ). Autocrine regulation of TGF-beta1-induced cell migration by exocytosis of ATP and activation of P2 receptors in human lung cancer cells. J. Cell Sci. 125 (Pt 21), 5051–5060.
Not in our library10.1242/jcs.104976
341.
Takai E. Tsukimoto M. Harada H. Kojima S. (2014 ). Autocrine signaling via release of ATP and activation of P2X7 receptor influences motile activity of human lung cancer cells. Purinerg. Signal 10 (3), 487–497.
Not in our library10.1007/s11302-014-9411-x
342.
Tamajusuku A. S. Villodre E. S. Paulus R. Coutinho-Silva R. Battasstini A. M. Wink M. R. (2010 ). Characterization of ATP-induced cell death in the GL261 mouse glioma. J. Cell Biochem. 109 (5), 983–991.
Not in our library10.1002/jcb.22478
343.
Tan C. Han L. I. Zou L. Luo C. Liu A. Sheng X. (2015 ). Expression of P2X7R in breast cancer tissue and the induction of apoptosis by the gene-specific shRNA in MCF-7 cells. Exp. Ther. Med. 10 (4), 1472–1478.
Not in our library10.3892/etm.2015.2705
344.
Taylor S. R. Gonzalez-Begne M. Dewhurst S. Chimini G. Higgins C. F. Melvin J. E. (2008 ). Sequential shrinkage and swelling underlie P2X7-stimulated lymphocyte phosphatidylserine exposure and death. J. Immunol. 180 (1), 300–308.
Not in our library10.4049/jimmunol.180.1.300
345.
Tsukimoto M. Tokunaga A. Harada H. Kojima S. (2009 ). Blockade of murine T cell activation by antagonists of P2Y6 and P2X7 receptors. Biochem. Biophys. Res. Commun. 384 (4), 512–518.
Not in our library10.1016/j.bbrc.2009.05.011
346.
Ulrich H. Ratajczak M. Z. Schneider G. Adinolfi E. Orioli E. Ferrazoli E. G. (2018 ). Kinin and Purine Signaling Contributes to Neuroblastoma Metastasis. Front. Pharmacol. 9, 500.
Not in our library10.3389/fphar.2018.00500
347.
Valera S. Hussy N. Evans R. J. Adami N. North R. A. Surprenant A. (1994 ). A new class of ligand-gated ion channel defined by P2x receptor for extracellular ATP. Nature 371 (6497), 516–519.
Not in our library10.1038/371516a0
348.
Vazquez-Cuevas F. G. Martinez-Ramirez A. S. Robles-Martinez L. Garay E. Garcia-Carranca A. Perez-Montiel D. (2014 ). Paracrine stimulation of P2X7 receptor by ATP activates a proliferative pathway in ovarian carcinoma cells. J. Cell Biochem. 115 (11), 1955–1966.
Not in our library10.1002/jcb.24867
349.
Vijayan D. Young A. Teng M. W. L. Smyth M. J. (2017 ). Targeting immunosuppressive adenosine in cancer. Nat. Rev. Cancer 17 (12), 709–724.
Not in our library10.1038/nrc.2017.86
350.
Virginio C. MacKenzie A. North R. A. Surprenant A. (1999 ). Kinetics of cell lysis, dye uptake and permeability changes in cells expressing the rat P2X7 receptor. J. Physiol. 519 Pt 2, 335–346.
Not in our library10.1111/j.1469-7793.1999.0335m.x
351.
Gut Microbiota and Cancer: From Pathogenesis to Therapy · 2019
No notice
352.
Walev I. Reske K. Palmer M. Valeva A. Bhakdi S. (1995 ). Potassium-inhibited processing of IL-1 beta in human monocytes. EMBO J. 14 (8), 1607–1614.
Not in our library10.1002/j.1460-2075.1995.tb07149.x
353.
Wang B. Sluyter R. (2013 ). P2X7 receptor activation induces reactive oxygen species formation in erythroid cells. Purinerg. Signal 9 (1), 101–112.
Not in our library10.1007/s11302-012-9335-2
354.
P2 receptor mRNA expression profiles in human lymphocytes, monocytes and CD34+ stem and progenitor cells · 2004
No notice
355.
Wang W. Xiao J. Adachi M. Liu Z. Zhou J. (2011 ). 4-aminopyridine induces apoptosis of human acute myeloid leukemia cells via increasing [Ca2+]i through P2X7 receptor pathway. Cell Physiol. Biochem. 28 (2), 199–208.
Not in our library10.1159/000331731
356.
Wei W. Ryu J. K. Choi H. B. McLarnon J. G. (2008 ). Expression and function of the P2X(7) receptor in rat C6 glioma cells. Cancer Lett. 260 (1-2), 79–87.
Not in our library10.1016/j.canlet.2007.10.025
357.
Wesselius A. Bours M. J. Arts I. C. Theunisz E. H. Geusens P. Dagnelie P. C. (2012 ). The P2X(7) loss-of-function Glu496Ala polymorphism affects ex vivo cytokine release and protects against the cytotoxic effects of high ATP-levels. BMC Immunol. 13, 64.
Not in our library10.1186/1471-2172-13-64
358.
White N. Butler P. E. Burnstock G. (2005 ). Human melanomas express functional P2 X(7) receptors. Cell Tissue Res. 321 (3), 411–418.
Not in our library10.1007/s00441-005-1149-x
359.
White E. Mehnert J. M. Chan C. S. (2015 ). Autophagy, Metabolism, and Cancer. Clin. Cancer Res. 21 (22), 5037–5046.
Not in our library10.1158/1078-0432.ccr-15-0490
360.
The C-terminus of human nucleotide receptor P2X7 is critical for receptor oligomerization and N-linked glycosylation. · 2013
Not checked
361.
Wiley J. S. Dao-Ung L. P. Gu B. J. Sluyter R. Shemon A. N. Li C. (2002 ). A loss-of-function polymorphic mutation in the cytolytic P2X7 receptor gene and chronic lymphocytic leukaemia: a molecular study. Lancet 359 (9312), 1114–1119.
Not in our library10.1016/s0140-6736(02)08156-4
362.
Wiley J. S. Dao-Ung L. P. Li C. Shemon A. N. Gu B. J. Smart M. L. (2003 ). An Ile-568 to Asn polymorphism prevents normal trafficking and function of the human P2X7 receptor. J. Biol. Chem. 278 (19), 17108–17113.
Not in our library10.1074/jbc.m212759200
363.
Wiley J. S. Sluyter R. Gu B. J. Stokes L. Fuller S. J. (2011 ). The human P2X7 receptor and its role in innate immunity. Tissue Antigens 78 (5), 321–332.
Not in our library10.1111/j.1399-0039.2011.01780.x
364.
Wilkaniec A. Gassowska M. Czapski G. A. Cieslik M. Sulkowski G. Adamczyk A. (2017 ). P2X7 receptor-pannexin 1 interaction mediates extracellular alpha-synuclein-induced ATP release in neuroblastoma SH-SY5Y cells. Purinerg. Signal. 13 (3), 347–361.
Not in our library10.1007/s11302-017-9567-2
365.
Wilson H. L. Wilson S. A. Surprenant A. North R. A. (2002 ). Epithelial membrane proteins induce membrane blebbing and interact with the P2X7 receptor C terminus. J. Biol. Chem. 277 (37), 34017–34023.
Not in our library10.1074/jbc.m205120200
366.
Woehrle T. Yip L. Elkhal A. Sumi Y. Chen Y. Yao Y. (2010 ). Pannexin-1 hemichannel-mediated ATP release together with P2X1 and P2X4 receptors regulate T-cell activation at the immune synapse. Blood 116 (18), 3475–3484.
Not in our library10.1182/blood-2010-04-277707
367.
Xia J. Yu X. Tang L. Li G. He T. (2015 ). P2X7 receptor stimulates breast cancer cell invasion and migration via the AKT pathway. Oncol. Rep. 34 (1), 103–110.
Not in our library10.3892/or.2015.3979
368.
Yan Z. Khadra A. Li S. Tomic M. Sherman A. Stojilkovic S. S. (2010 ). Experimental characterization and mathematical modeling of P2X7 receptor channel gating. J. Neurosci. 30 (42), 14213–14224.
Not in our library10.1523/jneurosci.2390-10.2010
369.
Yan J. Li X. Y. Roman Aguilera A. Xiao C. Jacoberger-Foissac C. Nowlan B. (2020 ). Control of Metastases via Myeloid CD39 and NK Cell Effector Function. Cancer Immunol. Res. 8 (3), 356–367.
Not in our library10.1158/2326-6066.cir-19-0749
370.
Yang Y. C. Chang T. Y. Chen T. C. Lin W. S. Chang S. C. Lee Y. J. (2016 ). Functional variant of the P2X7 receptor gene is associated with human papillomavirus-16 positive cervical squamous cell carcinoma. Oncotarget 7 (50), 82798–82803.
Not in our library10.18632/oncotarget.12636
371.
Yang J. Ma C. Zhang M. (2019 ). High glucose inhibits osteogenic differentiation and proliferation of MC3T3E1 cells by regulating P2X7. Mol. Med. Rep. 20 (6), 5084–5090.
Not in our library10.3892/mmr.2019.10790
372.
Yip L. Woehrle T. Corriden R. Hirsh M. Chen Y. Inoue Y. (2009 ). Autocrine regulation of T-cell activation by ATP release and P2X7 receptors. FASEB J. 23 (6), 1685–1693.
Not in our library10.1096/fj.08-126458
373.
Yoon M. J. Lee H. J. Kim J. H. Kim D. K. (2006 ). Extracellular ATP induces apoptotic signaling in human monocyte leukemic cells, HL-60 and F-36P. Arch. Pharm. Res. 29 (11), 1032–1041.
Not in our library10.1007/bf02969288
374.
Young C. N. Sinadinos A. Lefebvre A. Chan P. Arkle S. Vaudry D. (2015 ). A novel mechanism of autophagic cell death in dystrophic muscle regulated by P2RX7 receptor large-pore formation and HSP90. Autophagy 11 (1), 113–130.
Not in our library10.4161/15548627.2014.994402
375.
Young C. N. J. Chira N. Rog J. Al-Khalidi R. Benard M. Galas L. (2018 ). Sustained activation of P2X7 induces MMP-2-evoked cleavage and functional purinoceptor inhibition. J. Mol. Cell Biol. 10 (3), 229–242.
Not in our library10.1093/jmcb/mjx030
376.
Yu T. Junger W. G. Yuan C. Jin A. Zhao Y. Zheng X. (2010 ). Shockwaves increase T-cell proliferation and IL-2 expression through ATP release, P2X7 receptors, and FAK activation. Am. J. Physiol. Cell Physiol. 298 (3), C457–C464.
Not in our library10.1152/ajpcell.00342.2009
377.
Zanovello P. Bronte V. Rosato A. Pizzo P. Di Virgilio F. (1990 ). Responses of mouse lymphocytes to extracellular ATP. II. Extracellular ATP causes cell type-dependent lysis and DNA fragmentation. J. Immunol. 145 (5), 1545–1550.
Not in our library
378.
Zhang L. Y. Ibbotson R. E. Orchard J. A. Gardiner A. C. Seear R. V. Chase A. J. (2003 ). P2X7 polymorphism and chronic lymphocytic leukaemia: lack of correlation with incidence, survival and abnormalities of chromosome 12. Leukemia 17 (11), 2097–2100.
Not in our library10.1038/sj.leu.2403125
379.
Zhang X. J. Zheng G. G. Ma X. T. Yang Y. H. Li G. Rao Q. (2004 ). Expression of P2X7 in human hematopoietic cell lines and leukemia patients. Leuk. Res. 28 (12), 1313–1322.
Not in our library10.1016/j.leukres.2004.04.001
380.
Zhang Y. Cheng H. Li W. Wu H. Yang Y. (2019 a). Highly-expressed P2X7 receptor promotes growth and metastasis of human HOS/MNNG osteosarcoma cells via PI3K/Akt/GSK3beta/beta-catenin and mTOR/HIF1alpha/VEGF signaling. Int. J. Cancer 145 (4), 1068–1082.
Not in our library10.1002/ijc.32207
381.
Zhang Y. Ding J. Wang L. (2019 b). The role of P2X7 receptor in prognosis and metastasis of colorectal cancer. Adv. Med. Sci. 64 (2), 388–394.
Not in our library10.1016/j.advms.2019.05.002
382.
Zhao Q. Yang M. Ting A. T. Logothetis D. E. (2007 ). PIP(2) regulates the ionic current of P2X receptors and P2X(7) receptor-mediated cell death. Channels (Austin) 1 (1), 46–55.
Not in our library10.4161/chan.3914
383.
Zheng L. Zhang X. Yang F. Zhu J. Zhou P. Yu F. (2014 ). Regulation of the P2X7R by microRNA-216b in human breast cancer. Biochem. Biophys. Res. Commun. 452 (1), 197–204.
Not in our library10.1016/j.bbrc.2014.07.101
384.
Zitvogel L. Ma Y. Raoult D. Kroemer G. Gajewski T. F. (2018 ). The microbiome in cancer immunotherapy: Diagnostic tools and therapeutic strategies. Science 359 (6382), 1366–1370.
Not in our library10.1126/science.aar6918
385.
Intercellular Calcium Signaling Induced by ATP Potentiates Macrophage Phagocytosis · 2019
Not checked

Cited by papers we hold 1

Various Aspects of Calcium Signaling in the Regulation of Apoptosis, Autophagy, Cell Proliferation, and Cancer · 2020
No notice

Reads

Read by people on this page

None yet.

Checked or read by AI through naulon

None yet.

A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.

Are you an author?

Is this your paper?

Claim it to add your note and be paid when agents cite it. Free.